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The Achilles tendon is the largest and strongest tendon in the human body, as it is 
subjected to enormous tensile loads up to twelve times the body weight.1 Hierarchically 
arranged tendon collagen bundles transfer these forces from the calcaneus to the calf 
muscles during ankle movement.2 Despite its strength, the Achilles tendon is prone to 
overuse injuries also referred to as tendinopathy. Achilles tendinopathy is a common 
musculoskeletal condition with an annual incidence of 2-3 cases per 1000 patients 
in general medical practice.3 Approximately two-third of these patients is physically 
active or participating in sports, compared to one-third who has a sedentary lifestyle.4 
The disorder is, however, most frequent in running sports with up to 52% of high-level 
running athletes suffering from Achilles tendinopathy at least once in their lifetime.5 
The diagnosis tendinopathy is based on clinical findings, consisting of persistent 
localised tendon pain in relation to loading.6 Pathology located at the distal insertion 
on the calcaneus (<2 cm from the insertion) and the midportion area of the tendon 
(2-7 cm from the insertion) are generally considered to be two different clinical entities. 
These are distinguished since these parts of the tendon show different loading 
profiles and anatomy, which should be taken into consideration during treatment.7 In 
midportion Achilles tendinopathy, tensile loads are thought to be most prominent in 
the pathogenesis. In insertional Achilles tendinopathy, however, the Achilles tendon 
is also transversely compressed to the calcaneal bone which has been found to result 
in degenerative changes in tendon tissue due to compression forces.8 9 Treatment of 
Achilles tendinopathy is often challenging, and patients frequently receive multiple, 
often unsuccessful treatment modalities. Symptoms persist in 60% of patients 5 
years after start of treatment.8 10 
Below an overview will be provided on several topics of Achilles tendinopathy. We will 
focus on risk factors, imaging, and treatment options. 
Risk factors
Experts consider the aetiology to be multifactorial including both intrinsic factors (e.g. 
previous injury, plantar flexor strength, obesity) and extrinsic factors (e.g. change in 
load, environmental conditions, use of corticosteroids).11 The strength of the evidence 
for these risk factors remains uncertain, as there is no adequately performed recent 
systematic review evaluating these risk factors for Achilles tendinopathy.
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Imaging; a focus on neovascularisation and its role in pain 
sensation 
The role of imaging in diagnosing Achilles tendinopathy is currently topic of debate. 
When imaging is considered, the first choice is ultrasonography as it is cheap and easily 
accessible.12 Characteristic findings on ultrasonography include fusiform thickening of the 
Achilles tendon in anteroposterior direction and the presence of hypoechoic areas. Both 
findings are caused by disorganisation of the hierarchically arranged tendon collagen 
bundles, with the attraction of water in the extracellular matrix.13 Additionally, increased 
blood supply is usually present. In a normal state, small blood vessels run from proximally 
and distally inside the Achilles tendon towards the midportion area of the tendon (2-7 
cm from the insertion). As a result, the midportion area of the Achilles tendon forms 
a watershed area and as a consequence physiologically has the lowest blood supply.14 
15 An imaging technique to visualise blood flow is Doppler ultrasonography.16 Doppler 
ultrasonography uses the Doppler effect to measure movement of tissues, most often 
blood in the human body. In a normal state, blood flow in asymptomatic tendons is too 
low to visualise with Doppler ultrasonography.17 Therefore, the presence of Doppler 
flow usually represents an abnormal increase in blood flow. In tendon tissue, Doppler 
flow has been found to be present within and around the Achilles tendon in 50-100% 
of the symptomatic tendons, compared to 0-30% of the asymptomatic tendons.18-22 
This Doppler flow is considered to reflect the presence of newly formed blood vessels 
(neovascularisation) with an increased blood supply.14 23 These newly formed blood 
vessels originate from the Kagers’ fat pad anterior of the Achilles tendon and infiltrate 
the Achilles tendon diffusely with a tortuous course.14 As a result, Doppler flow is initially 
most often present at the anterior aspect of the Achilles tendon in symptomatic tendons. 
When Doppler flow increases, it can also be visualised at the dorsal aspect of the Achilles 
tendon.19 Most frequently these neovessels are thought to be secondary to the failed 
healing of tendinopathic tissue, but to date this is uncertain. 
Treatment
Managing Achilles tendinopathy is often challenging for both patients and their 
healthcare providers. The main treatment modalities offered to patients with Achilles 
tendinopathy are wait-and-see, exercise therapy, injections, shockwave therapy, 
orthosis, medication, and surgery.7 Most patients receive multiple treatments over 
time, resulting in increased healthcare consumption.10 It is generally accepted in 
clinical care that exercise therapy and load management should be part of the initial 
treatment. As both short-term and long-term outcome of initial treatment are often 
unsatisfactory, numerous additional treatment options have been investigated.24 25 To 
date, the comparative effectiveness of all these treatments has never been examined. 
Being faced with so many potentially effective treatments, it is challenging for healthcare 
providers to adequately treat patients using a shared decision making model. 
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To evaluate symptoms and activity levels in patients with Achilles tendinopathy the 
Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire is a valid and 
reliable tool and most often used in both a clinical and a research setting.26 The VISA-A 
score ranges from 0 to 100; 100 indicates no pain with full activity level and the score 
decreases with increasing severity of symptoms. The questionnaire has been shown 
to be reliable, but to date the clinical relevance of the outcome is uncertain as the 
change that an individual patient would identify as important is unknown. This change 
is called the minimal clinically important difference (MCID) and this score is important 
to determine the effectiveness of a certain treatment.
Some novel interventions go off the beaten path of restoring tendon structure 
organisation, but primarily focus on the modulation of pain in tendinopathy. This shift 
has took place as tendon structure disorganisation is seen in symptomatic tendons, 
however, this disorganisation has not been found to be directly related to symptoms.27 
In other words, if there is more severe tendon structure disorganisation, this does not 
directly result in an increased symptom severity. Two mechanisms could play a role 
in persisting pain in Achilles tendinopathy. First, nerve structures accompanying the 
neovascularisation have been found in histopathological examination.28 These nerve 
structures could play a significant role in the chronic aspect of the pain in Achilles 
tendinopathy.14 29 Indeed, a large study showed an association between the degree 
of ultrasonographic Doppler flow and the severity of symptoms.18 Second, altered 
central pain processing may play an important role in persisting symptoms, with 
pathophysiological pain (central sensitisation) as a result.30 31 Due to these changes 
in central pain processing, the disorder could become resistant to tissue-based 
treatment options that are currently available.32 Isometric exercises of several muscle 
groups have been found to result in an immediate analgesic effect, which suggests 
these exercises influence central pain processing.33-36 As a consequence, isometric 
exercises are frequently being used as ‘in-season pain management’.37 One previous 
study specifically investigated the role of isometric exercises of the calf muscles 
in patients suffering from Achilles tendinopathy and found no difference after the 
performance of these exercises.38 The power of these contradictory studies was, 
however, limited and a clinically relevant immediate effect could not be excluded as 
adequate control groups were lacking. 
Another novel intervention focussing on the modulation of pain is a high-volume 
injection, in which a large amount of fluid is injected in the peritendinous area with 
the aim to obliterate the neovascularisation and the adjacent nerve structures.29 Very 
promising short-term (6-12 weeks) results on the VISA-A score were found in several 
case series.29 39 40 Consequently, this therapy is increasingly used in the clinical setting. 
The effectiveness has, however, not been tested in a large robustly designed study. 
11
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Aim and outline of this thesis
The general aim of this thesis is to evaluate risk factors, imaging, and treatment 
options in patients with Achilles tendinopathy.
We were at first interested to identify clinical risk factors for Achilles tendinopathy, 
as these could prove useful for prevention and treatment of Achilles tendinopathy. 
In Chapter 2 we conducted a systematic review of the literature to identify these 
risk factors. This will provide the level of evidence for all clinical risk factors to inform 
future prevention and treatment strategies. 
Neovascularisation, as usually seen during ultrasonography, is of increasing 
interest in the pathophysiology of Achilles tendinopathy. It is, therefore, important 
to adequately evaluate Doppler flow following treatment to further investigate the 
role of neovascularisation in tendinopathy. Most previous studies used the semi-
quantitative modified Öhberg score to evaluate Doppler flow. As this outcome 
measure is observer-dependent and has a ceiling effect with higher degrees of 
neovascularisation, we investigated a quantitative method in which the amount of 
coloured pixels during power Doppler ultrasonography is measured. In Chapter 3 
we evaluated the inter-observer reliability of both the modified Öhberg score and a 
surface area quantification (SAQ) method in patients with chronic midportion Achilles 
tendinopathy.
In Chapter 4 we determined the minimal clinically important difference (MCID) 
and patient acceptable symptom state (PASS) for the Victorian Institute of Sports 
Assessment-Achilles (VISA-A) score that is most often used in studies to evaluate 
symptom severity in Achilles tendinopathy. Both scores are currently not very well 
studied and are very important to determine the effectiveness of the available 
treatment options. 
In Chapter 5 we evaluated the comparative effectiveness of all available treatments 
for Achilles tendinopathy with a living systematic review with network-meta-analysis. 
This living systematic review will be updated regularly, which allows for a contemporary 
evidence synthesis for clinical practice. 
The last decades the number of available treatments for Achilles tendinopathy 
increased rapidly, but scientific evidence for these treatments is often missing. 
Novel treatments for Achilles tendinopathy increasingly focus on the modulation of 
pain in tendinopathy. This shift seems to occur as severity of local tendon structure 
disorganisation has been found to be not directly related to the amount of symptoms. 
Isometric exercises for lower-limb tendinopathies have also been found to influence 
central pain processing. As a result, these exercises are often suggested as initial 
management for Achilles tendinopathy. Current evidence is, however, heterogeneous 
and sample sizes in previous studies were small. We performed a quasi-randomised 
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clinical trial in Chapter 6 in which we investigated whether isometric exercises 
result in an immediate analgesic effect in patients with chronic midportion Achilles 
tendinopathy.
In Chapter 7 we investigated the effectiveness of the high-volume injection, which 
is considered to be a very promising treatment option according to previous case 
series and a small randomised clinical trial. We performed a randomised clinical trial 
to study whether a high-volume injection improves clinical outcome in addition to 
usual care for patients with chronic midportion Achilles tendinopathy. 
The mechanism of the high-volume injection is to date unclear. The hypothesised 
mechanism involved destruction of the neovascularisation and the adjacent nerve 
structures. The mechanical effect of a high-volume injection is explored in Chapter 8. 
We evaluated ultrasonographic Doppler flow to explore the effect of the high-volume 
injection on the neovascularisation during the injection procedure and at short- and 
intermediate term follow-up. 
In Chapter 9 a general discussion regarding the results of the different studies in this 
thesis is provided. Clinical relevance, implications for research and treatment and 
future research are discussed. 
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Clinical risk factors for 
Achilles tendinopathy:  
a systematic review
Arco C van der Vlist, Stephan J Breda, Edwin HG Oei, Jan AN Verhaar, 
Robert-Jan de Vos




Background: Achilles tendinopathy is a common problem but its exact aetiology 
remains unclear.
Objective: To evaluate the association between potential clinical risk factors and 
Achilles tendinopathy.
Design: Systematic review.
Data sources: The databases Embase, MEDLINE Ovid, Web of Science, Cochrane 
Library and Google Scholar were searched up to February 2018.
Eligibility criteria: To answer our research question, cohort studies investigating risk 
factors for Achilles tendinopathy in humans were included. We restricted our search 
to potential clinical risk factors (imaging studies were excluded). 
Results: We included 10 cohort studies, all with a high risk of bias, from 5111 
publications identified. There is limited evidence for nine risk factors: (1) prior lower 
limb tendinopathy or fracture, (2) use of ofloxacin (quinolone) antibiotics, (3) an 
increased time between heart transplantation and initiation of quinolone treatment 
for infectious disease, (4) moderate alcohol use, (5) training during cold weather, (6) 
decreased isokinetic plantar flexor strength, (7) abnormal gait pattern with decreased 
forward progression of propulsion, (8) more lateral foot-roll over at the forefoot 
flat phase and (9) creatinine clearance of <60 mL/min in heart transplant patients. 
Twenty-six other putative risk factors were not associated with Achilles tendinopathy, 
including being overweight, static foot posture and physical activity level. 
Conclusion: From an ocean of studies with high levels of bias, we extracted nine clinical 
risk factors that may increase a person’s risk of Achilles tendinopathy. Clinicians may 
consider ofloxacin use, alcohol consumption and a reduced plantar flexor strength as 
modifiable risk factors when treating patients with Achilles tendinopathy. 




The Achilles tendon is the largest and strongest tendon in the human body, yet it is 
prone to injury such as tendinopathy. The presence of Achilles tendon pain, swelling 
and an impaired load-bearing capacity indicate Achilles tendinopathy (AT).1-3 From 
a clinical perspective, insertional and midportion Achilles tendinopathy should 
be distinguished since these are two separate entities with different treatment 
approaches.4 AT is most frequently seen in elite running athletes, with a lifetime risk of 
52%.5 It should, however, be noted that one-third of all AT patients have a sedentary 
lifestyle.6 This emphasizes that there is probably a broad spectrum of potential risk 
factors for Achilles tendinopathy, yet the exact aetiology remains uncertain.7 
Over the last decades, various determinants have been proposed as risk factors in 
the development of AT. A recent systematic review examined risk factors for AT with 
a primary focus on genetic aspects.8 They found that certain genetic determinants 
may contribute to the development of AT, such as genetic contributors to collagen 
structure formation and tendon homeostasis. However, results were ambiguous due 
to the methodology in the publications included. These publications had mixed study 
designs and the number of non-genetic clinical risk factors was limited. Therefore, 
there is a need to evaluate clinical risk factors in the development of AT with an 
extensive literature search and robust methodological design. 
In this study, we systematically review the literature regarding the potential clinical 
risk factors that have been investigated for AT. This provides the level of evidence for 
all known clinical risk factors to inform future prevention and treatment strategies.
Methods
Protocol and registration
The protocol for this systematic review was prospectively registered in the 
international PROSPERO database. Protocol details can be accessed via http://www.
crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017053258. A protocol 
revision was performed in July 2017 from midportion AT as site of injury to AT in 
general (insertional and midportion AT combined). This was done as we observed 
during data extraction that a substantial number of publications did not specify the 
specific location. 
Eligibility criteria
Publications were eligible for inclusion when there was (1) a potential risk factor 
investigated in relation to AT and (2) a diagnosis of AT based on clinical findings (local 
pain and impaired load-bearing capacity). We restricted our selection to prospective 
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and retrospective cohort studies written in English. A determinant was considered to 
be a potential clinical risk factor if no extensive examination (eg. biopsies) had been 
performed. Publications were excluded if there was: (A) no adequate control group (eg. 
contralateral Achilles tendon), (B) a preclinical study design or (C) an imaging study design 
(eg. potential risk factors derived from MRI or ultrasound examinations). Imaging studies 
were excluded, since these are regularly not directly available in the sports physician 
consultation room. For an overview of imaging, we refer to a recent systematic review.9
We also aimed to identify potential novel risk factors as secondary outcome measure 
by including cross-sectional studies. While the level of evidence from cross-sectional 
studies is lower than that from cohort studies, they might identify interesting factors 
to explore in future research.
Literature search strategy and information sources
We conducted a sensitive search strategy for multiple databases with the assistance 
of a medical librarian (WM Bramer). The following databases were searched up to 
12 February 2018: Embase, MEDLINE Ovid, Web of Science, Cochrane Library and 
Google Scholar. The search strategy is shown in online supplementary appendix 1. 
Study selection and data extraction
Titles and abstracts were screened by two independent reviewers (ACvdV and RJdV) 
to identify eligible publications. Disagreements were solved by consensus, with 
the involvement of a third review author (EHGO) if necessary. Data extraction was 
performed by one author (ACvdV) and a data check was performed by a second author 
(SJB) for 100% of the primary outcomes and for 20% of the other data. This has been 
shown to be a methodologically sound procedure.10 The potential risk factors were 
extracted and grouped into patient characteristics (modifiable and non-modifiable), 
biomechanical factors, pre-existing diseases, medication and training factors. AT 
subgroup analysis results are presented in case subgroup analyses were performed 
in studies describing associations for multiple injuries. If multiple populations with AT 
were assessed in a single publication, only combined results are presented. 
Risk of bias assessment
Two reviewers (ACvdV and SJB) independently assessed the methodological quality of 
all included prospective (level of evidence II) and retrospective cohort studies (level 
of evidence III). No risk of bias assessment was performed for cross-sectional studies 
(level of evidence IV), since these studies are considered to be of high risk of bias for 
the purpose of this review. 
21
2
To assess risk of bias, we used a standardised set of criteria based on modified 
questions of existing quality assessment tools (table 1).11-13 This tool has previously 
been used in a systematic review on risk factors for Achilles tendon rupture.14 If a 
criterion was met, one point was given. No points were given if the criterion was not 
met or when it was unclear if the specific criterion was met. A maximum score of 10 
points could be obtained. Publications were considered to be of low risk of bias if: (1) 
a total score of 6 points or more was given and (2) 1 point was given to criterion 6, 7, 
8 and 10.14 
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Table 1. Risk of bias assessment tool




• Did they have a ‘study question’ or ‘main aim’ or 
‘objective’?
• The question addressed should be precise and 
relevant in light of available literature
• To be scored adequate the aim of the study should 










• Did the authors say: ‘consecutive patients’ or ‘all 
patients during period from … to….’ or ‘all patients 











• Did the authors report how many eligible patients 












• Did they say ‘prospective’, ‘retrospective’ or ‘follow- 
up’?
• The study is not prospective when it is a chart 








• Did they report the association between the 
potential risk factors and manifestation of Achilles 
tendinopathy as outcome? The valid outcome 









• To be judged as adequate, the following two aspects 
had to be positive:
• Outcome and potential risk factors had to be 
measured independently
• The outcome and potential risk factors for both 









• For studies where the determinant measures are 
shown to be valid and reliable, the question should 
be answered adequate. For studies that refer to 
other work that demonstrates the determinant 









• To be judged as adequate the following two aspects 
had to be positive:
• Did they report the losses to follow-up?





• To be judged as adequate the following two aspects 
had to be positive:
• There must be a description of the relationship 
between the potential risk factors and Achilles 
tendinopathy (with information about the 
statistical significance)
• Was there adjustment for possible confounders 
(age, sex, body mass index) by multivariate 
analysis?
□ □
For each methodological criterion that is met 1 point is given. If the criterion was not met zero points were 
given. Publications were considered to be of low risk of bias if (1) a total score of at least 6 points was given 
and (2) 1 point was given to questions 6, 7, 8 and 10 (marked with the grey columns). 
Data synthesis
A subgroup analysis was initially planned for insertional and midportion AT; however, 
we revised the PROSPERO protocol (revision date 20 July 2017) because a substantial 
number of publications did not specify the AT location. Homogeneity of the data was 
evaluated, and if data could not be pooled because of heterogeneity, a best evidence 
synthesis based on the study of van Tulder et al. was carried out for each potential 
risk factor.15 
- Strong evidence: ≥2 studies with high quality and generally consistent findings 
in all studies (≥75 % of the studies reported consistent findings). 
- Moderate evidence: one high-quality study and ≥2 low-quality studies and 
generally consistent results (≥75 % of the studies reported consistent findings). 
- Limited evidence: generally consistent findings in ≥1 low-quality study (≥75 % 
of the studies reported consistent findings). 
- Conflicting evidence: <75 % of the studies reporting consistent findings. 





We identified 5,111 potentially relevant publications and after removing duplicates, 
3225 remained. After screening title and abstract, we assessed 109 publications 
in full-text. Fifty-four publications were excluded for different reasons after full-
text evaluation, as shown in the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) flow chart (figure 1). We included the remaining 55 
publications for analysis. 
Figure 1. PRISMA 2009 flow diagram of study selection process. PRISMA, Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses.
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Characteristics of the included publications
We included eight prospective cohort studies16-23 and two retrospective cohort 
studies.24 25 Additionally, 45 cross-sectional studies were included.5 26-69 The 
characteristics and main findings of the included studies are summarised in table 2 
for the cohort studies and online supplementary appendix 2 for the cross-sectional 
studies. 
Of the 10 cohort studies, five studies included only participants with midportion AT 
and five studies did not specify the AT location. Sample sizes of the included cohort 
studies ranged from 69 to 80,106 participants (median 285) with the number of 
AT cases ranging from 5 to 450 (median 18). Mean age ranged from 18 years old 
to 59 years old (median 21). This relatively young median age was caused by the 
profession of most of the populations investigated (military recruits in five studies, 
students in one study). There was a greater proportion of male participants in seven 
cohort studies, compared with two studies in which there was a greater proportion 
of female participants (median percentage males 78%). Data regarding the number 
of participants, mean age or sex was incomplete in two studies. The follow-up period 
for the prospective cohort studies ranged from 6 weeks to 2 years (median 39 weeks). 
Of the 45 cross-sectional studies, 15 studies included only participants with 
midportion AT, one study included patients with insertional AT and 29 studies did 
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RC NR 149 (14); Heart 
transplant patients 
who were prescribed 
quinolones





• A creatinine clearance  <60 ml/min  was associated with AT compared to a creatinine 
clearance ≥ 60 ml/min (OR 6.14; 95% CI 1.23-30.64; p=0.03)
• increased time (in years) between heart transplantation and initiation of quinolone treatment 
for infectious disease was associated with AT (OR 1.39; 95% CI 1.11-1.74; p=0.005)
• No associations were found for age, sex, levofloxacin use and daily prednisone dose (mg)
5
Hein et al. 
(2014) 20
PC 52 269 (10); Recreational 
runners





• No statistical analyses were performed 4
Kaufman et al. 
(1999) 21
PC 104 449 (30); Navy Sea, 
Air and Land (SEAL) 
candidates





• A tight ankle dorsiflexion with knee extended (<11.5°) was associated with AT compared to a 
normal dorsiflexion (11.5-15.0°) (RR 3.57; 95% CI 1.01-12.68; p<0.05) 
• No associations were found for hindfoot inversion, hindfoot eversion, static arch index of the 
foot, dynamic arch index of the foot, dorsiflexion of the ankle with the knee bent 
5
Mahieu et al. 
(2006) 16
PC 6 69 (10); Officer cadets 100.0% 18.4 ± 1.3 Midportion 
Achilles 
tendinopathy
• Isokinetic plantar flexion strength at 30 degrees/s was decreased in patients who developed 
AT for both the right and the left leg and at 120 degrees/s for the right leg (p=0.042, p=0.036 
and p=0.029 respectively). Plantar flexion strength was measured using the Cybex Norm 
dynamometer, which measures strength at constant velocity. 
• No associations were found for weight, BMI, length, physical activity level, Achilles tendon 
stiffness, isokinetic plantar flexion strength at 120 degrees/s for the left leg, explosive 
gastrocnemius-soleus muscle strength (standing broad jump test) and passive and active 
ankle joint range of motion outcomes.
4
Milgrom et al. 
(2003) 22
PC 14 1405 (95);  Infantry 
recruits
100.0% 18.7 ± 7 Midportion 
Achilles 
tendinopathy
• An increase in AT was seen when training in the winter season compared to summer training 
(p=0.001)
• No differences were found in height, weight, BMI, external rotation of the hip, tibial 
intercondylar distance, arch type, physical fitness performance (2-km run and maximum 
number of chin-ups and sit-ups done) and shoe type
4
Owens et al. 
(2013) 17
PC 52 80 106 (450); Military 
service members





• Being overweight and obesity were associated with AT compared to underweight or normal 
weight (AOR 1.29, 95% CI 1.04-1.59 and  AOR 1.59, 95% CI 1.16-2.17 respectively) 
• A prior lower limb tendinopathy or fracture was associated with AT (AOR 3.87, 95% CI 3.16-4.75)
• Moderate alcohol use (7-13 units per week for men, 4-6 units per week for women) was 
associated with AT compared to no alcohol use (AOR 1.33, 95% CI 1.00-1.76)
• A birth year of 1980 and later was associated with a decreased risk for AT compared to a 
birth year before 1960 (AOR 0.62, 95% CI 0.38-1.00)
• No associations were found for sex, ethnicity, smoking status and heavy alcohol use (14+ 
units per week for men, 7+ units per week for women)
6
Rabin et al. 
(2014) 18
PC 26 70 (5); Military recruits 100.0% 19.6 ± 1.0 Midportion 
Achilles 
tendinopathy
• Every one-degree increase in ankle dorsiflexion with the knee bent was associated with a 
decreased risk for AT (OR 0.77; 95% CI 0.59-0.94)
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mean ± SD 
(years)
Location injury Risk factors (Risk ratio, odd’s ratio, hazard ratio) Quality 
score 
(points)
Van Ginckel et 
al. (2008) 19
PC 10 129 (10); Novice runners 14.7% 39 ± 10 Midportion 
Achilles 
tendinopathy
• An increased total anterior displacement of the Y-component of the Center of Force was 
associated with a decreased risk for AT (OR 0.919; 95% CI 0.859-0.984; p=0.015)
• A more medial directed force distribution underneath the forefoot at forefoot flat was 
associated with a decreased risk for AT (OR 0.000; 95% CI 0.000-0.158; p=0.016)
• No associations were found for age, height, weight, BMI or physical activity score
6
Van der 
Linden et al. 
(1999) 25
RC NR 10 800 (8); Patients 
using fluoroquinolones 
(index group) 












• The use of ofloxacin was associated with AT compared to the reference group (AOR 10.1; 95% 
CI 2.20-46.04)
• No associations were found for fluoroquinolones as a group, ciprofloxacin use and 




PC 104 300 (27); first-year 
students
47% 18.0 ± 0.8 Midportion 
Achilles 
tendinopathy
• Female sex was associated with AT (HR 2.82, 95%  CI 1.16-6.87)
• Height and body weight were increased in patients with AT (p=0.028 and p=0.015)
• No association was found for a pronated foot posture 
• No differences were found for BMI, rating of perceived exertion, hours of sports participation 
and leg dominance 
7
AOR, Adjusted odds ratio; AT, Achilles tendinopathy; BMI, Body Mass Index; CI, Confidence interval; CON; 
Unaffected controls; HR, Hazard ratio; km, kilometer; NA, not applicable; OR, Odds ratio; PC, Prospective 
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cohort study; RC, Retrospective cohort study; RR, Risk ratio; SD, Standard deviation.
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Risk of bias assessment
All 10 cohort studies were considered to be of high risk of bias according to the 
predefined criteria (tables 1 and 3). Seven cohort studies scored six points or higher; 
however, they were lacking clinical examination as valid outcome (two studies), a 
valid and reliable determinant measure (four studies), an unbiased assessment of 
the study outcome (one study) and/or adequate statistical analyses (three studies). 
As a result, at best, a limited evidence for the association between the potential risk 
factor and tendinopathy could be detected. Results of the best evidence synthesis are 
presented in table 4. 
Table 3. Risk of bias assessment scores of the ten included cohort studies




1 2 3 4 5 6 7 8 9 10
5Barge-
Caballero et al. 
(2008) 24
1 1 1 0 0 0 0 1 0 1 High
Hein et al. 
(2014) 20
1 0 1 1 1 0 0 0 0 0 4 High
Kaufman et al. 
(1999) 21
1 1 0 1 1 1 1 0 0 0 5 High
Mahieu et al. 
(2006) 16
0 1 0 1 1 1 1 0 0 1 6 High
Milgrom et al. 
(2003) 22
0 0 0 1 1 1 0 0 0 0 3 High
Owens et al. 
(2013) 17
1 1 0 1 1 0 1 1 0 0 6 High
Rabin et al. 
(2014) 18
1 1 1 1 1 1 1 0 1 1 9 High
Van der Linden 
et al. (1999) 25
1 1 1 0 1 0 1 1 0 0 6 High
Van Ginckel et 
al. (2008) 19
1 0 1 1 1 1 1 0 0 1 7 High
Wezenbeek et 
al. (2018) 23
1 1 1 0 1 1 0 1 0 1 7 High
Outcomes of the risk of bias assessment tool as presented in table 1. Publications were considered to be of 
low risk of bias if (1) a total score of at least 6 points was given and (2) 1 point was given to questions 6, 7, 8 
and 10 (marked with the grey columns).
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Table 4. Potential risk factors investigated in the ten cohort studies as potential risk factor for 
Achilles tendinopathy. Associations found in this systematic review are marked with the grey 
columns.




Age Barge-Caballero = 24, Owens birth 
year >1980 ↓ 17, Van Ginckel = 19
Conflicting evidence
Sex Barge-Caballero = 24, Owens = 17, 
Wezenbeek female ↑ 23
Conflicting evidence
Ethnicity Owens = 17 Limited evidence for no 
association
Height Mahieu = 16, Milgrom = 22, Van Ginckel 
= 19, Wezenbeek ↑ 23
Limited evidence for no 
association
Prior lower limb 
tendinopathy or fracture
Owens ↑ 17 Limited evidence for 
positive association
Patient characteristics (modifiable)
Body Mass Index Owens BMI >25.0 ↑17, Mahieu = 16, 
Milgrom = 22, Rabin = 18, Van Ginckel = 
19, Wezenbeek = 23
Limited evidence for no 
association
Body weight Mahieu = (18), Milgrom = 22, Van 
Ginckel = (23), Wezenbeek ↑ 23
Limited evidence for no 
association
Alcohol use Owens 7-13 units per week for men, 
4-6 units per week for women↑ 17, 
Owens 14+ units per week for men, 
7+ units per week for women =17
Limited evidence for 
positive association 
(moderate alcohol use)
Smoking Owens = 17 Limited evidence for no 
association
Physical activity level and 
performance
Mahieu physical activity level = 16, 
Van Ginckel physical activity level= 19, 
Milgrom physical activity performance 
(2-km run and maximum number of 
chin-ups and sit-ups) = 22, Wezenbeek 
= 23
Limited evidence for no 
association
Biomechanical factors
Shoe type Milgrom = 22 Limited evidence for no 
association




dorsiflexion with knee 
extended 
Kaufman <11.5° ↑ 21, Mahieu = 16 Conflicting evidence
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dorsiflexion with the 
knee bent
Mahieu = 16, Rabin ↓ 18, Kaufman = 21 Conflicting evidence
Hindfoot inversion Kaufman = 21 Limited evidence for no 
association
Hindfoot eversion Kaufman = 21 Limited evidence for no 
association
Static arch index of the 
foot
Kaufman = 21, Milgrom = 22 Limited evidence for no 
association
Dynamic arch index of 
the foot
Kaufman = 21 Limited evidence for no 
association
Pronated foot posture Wezenbeek = 23 Limited evidence for no 
association
Increase in isokinetic 
plantar flexor strength 
at 30 degrees/s (low 
velocity)





Mahieu = 16 Limited evidence for no 
association
External rotation of the 
hip




Milgrom = 22 Limited evidence for no 
association
lower extremity quality 
of movement test
Rabin = 18 Limited evidence for no 
association
Increased total 
displacement of the 
Y-component of the 
Centre of Force











Barge-Caballero ↑ 24 Limited evidence for 
positive association
increased time between 
heart transplantation 
and initiation of 
quinolone treatment for 
infectious disease










Van der Linden = 25 Limited evidence for no 
association
Levofloxacin Barge-Caballero = 24 Limited evidence for no 
association
Ofloxacin Van der Linden ↑ 25 Limited evidence for 
positive association
Ciprofloxacin Van der Linden = 25 Limited evidence for no 
association
Norfloxacin Van der Linden = 25 Limited evidence for no 
association
Daily prednisone dose Barge-Caballero = 24 Limited evidence for no 
association
Training factors
Training in the winter 
season
Milgrom ↑ 22 Limited evidence for 
positive association
= no association; ↑ positive association; ↓protective association
Risk factors
Patient characteristics (non-modifiable)
Age There is conflicting evidence that age affects the risk for AT. One cohort study 
reported in 2013 that a birth year of 1980 or later is associated with a decreased risk 
for AT.17 Two cohort studies showed no association.19 24 
Sex There is conflicting evidence that sex affects the risk for AT. One cohort study 
reported that being female is associated with AT.23 No association was demonstrated 
in two cohort studies.17 24 
Ethnicity There is limited evidence that ethnicity does not affect the risk for AT. One 
cohort study reported no increased risk for white (non-Hispanic), black (non-Hispanic) 
or other ethnicity.17 
Height There is limited evidence that height does not affect the risk for AT. No 
association was found in three cohort studies.16 19 22 One cohort study reported an 
increased height in patients with AT.23 
Prior lower limb tendinopathy or fracture There is limited evidence that a prior lower 
limb tendinopathy or fracture increases the risk for AT. One cohort study reported 
that a prior lower limb tendinopathy (plantar fascia, Achilles or patellar) or fracture 




Body Mass Index (BMI) and body weight There is limited evidence that BMI or body 
weight do not affect the risk for AT. No association was found in five cohort studies 
for BMI 16 18 19 22 23 and in three cohort studies for body weight.16 19 22 One cohort study 
found that being overweight (BMI ≥25.0) and obesity (BMI ≥30.0) are associated 
with AT.17 Another cohort study found that body weight is increased in people who 
develop AT.23 
Alcohol use There is limited evidence that moderate alcohol use increases the risk 
for AT. Moderate alcohol use was defined as 7-13 units per week for men and 4-6 
units per week for women. One cohort study reported that moderate alcohol use is 
associated with AT compared with no alcohol use. No association was found for light 
alcohol use or heavy alcohol use compared with no alcohol use. 17 
Smoking There is limited evidence that smoking is not associated with AT based on 
one cohort study.17  
Physical activity level, physical activity performance and hours of sports participation 
There is limited evidence that physical activity level, physical activity performance 
or hours of sports participation do not affect the risk for AT. Two cohort studies 
found no association between the physical activity level measured with the Baecke 
questionnaire and AT.16 19 One cohort study found no association between the physical 
activity performance (2-km run and maximum number of chin-ups and sit-ups) and 
AT.22 Another cohort study found no differences in hours of sports participation 
between patients with AT and unaffected controls.23
Biomechanical factors
Shoe type There is limited evidence that the type of shoes is not associated with AT. 
One cohort study found no difference in AT incidence between modified basketball 
shoes and standard lightweight infantry boots.22 
Leg dominance There is limited evidence that leg dominance is not associated with AT 
based on one cohort study.23 
Static and dynamic properties of the foot There is limited evidence that hindfoot inversion, 
hindfoot eversion, the static arch index of the foot, the dynamic arch index of the foot 
and a pronated foot posture do not increase the risk for AT. One cohort study reported 
that hindfoot inversion, hindfoot eversion, the static arch index of the foot and the 
dynamic arch index of the foot are not associated with AT.21 Another cohort study 
also found no association between the static arch index of the foot and AT.22 The third 
cohort study found no association between a pronated foot posture and AT.23
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Static and dynamic properties of the ankle There is conflicting evidence that a decreased 
non-weight-bearing ankle dorsiflexion is associated with AT. One cohort study found 
that a limited ankle dorsiflexion (<11.5°) with the knee extended is associated with 
AT compared with a normal ankle dorsiflexion (11-15°).21 Another cohort study 
evaluating ankle dorsiflexion with the knee extended did not show an association.16 
One cohort study found that a one degree increase in ankle dorsiflexion with the 
knee bent is associated with a decreased risk for AT.18 Two cohort studies evaluating 
ankle dorsiflexion with the knee bent demonstrated no association.16 21
Limited evidence was found that an increased isokinetic plantar flexor strength at 
30°/s (low velocity) is associated with a decreased risk for AT. No association between 
explosive gastrocnemius-soleus muscle strength (measured with the standing broad 
jump test) and AT was found in this study.16 
Static and dynamic properties of the knee There is limited evidence that the tibial 
intercondylar distance is not associated with AT based on one cohort study.22
Static and dynamic properties of the hip There is limited evidence that the amount of 
external rotation of the hip is not associated with AT based on one cohort study.22 
Gait analysis There is limited evidence that an abnormal gait pattern with decreased 
forward progression of the propulsion and a more lateral foot-roll over at the forefoot 
flat phase are associated with AT. One cohort study reported a protective association 
per millimetre increase in total displacement of the Y-component of the centre of 
force. This cohort study also reported a decreased risk for AT if the mediolateral 
pressure distribution ratio underneath the forefoot at forefoot flat phase increased.19 
No associations were found in another cohort study for the lower extremity quality 
of movement test.18 
Pre-existing diseases
Renal dysfunction There is limited evidence that a creatinine clearance <60 mL/min 
is associated with AT in heart transplant patients. One cohort study reported an 
increased risk to develop AT in this specific group compared with heart transplant 
patients with a creatinine clearance ≥60 mL/min.24 
Heart diseases There is limited evidence that an increased time (in years) between 
heart transplantation and initiation of quinolone treatment for infectious disease is 
associated with AT. One cohort study described this association.24 This outcome was 
solely investigated in heart transplant patients that all received quinolone treatment. 
Therefore, heart transplantation and quinolone treatment cannot be evaluated as 




Fluoroquinolones There is limited evidence that the use of ofloxacin is associated with 
AT. One cohort study found an increased risk to develop AT when using ofloxacin 
compared with other antibiotic drugs (without fluoroquinolones).25 This cohort study 
found no associations for fluoroquinolones as a group, ciprofloxacin and norfloxacin. 
Another cohort study found no association between levofloxacin use and AT 
specifically in heart transplant patients compared with no use of levofloxacin.24 
Corticosteroids There is limited evidence that daily oral prednisone dose is not 
associated with AT based on one cohort study.24 
Training factors
Training season There is limited evidence that training during cold weather is 
associated with AT. One cohort study found that the incidence of AT increased during 
recruit winter training compared with summer training.22
Potential risk factors evaluated in cross-sectional studies
In the 45 cross-sectional studies 296 risk factors were investigated. 115 associations 
were found, mostly consisting of biomechanical factors (56 associations) or genetic 
factors (30 associations). All data are presented in online supplementary appendix 2. 
Discussion 
Summary of main findings
This is the first high-quality systematic review of clinical risk factors for Achilles 
tendinopathy. We identified 10 cohort studies, all of which had a high risk of bias and 
45 cross-sectional studies. 
There is limited evidence for the following nine risk factors: (1) prior lower limb 
tendinopathy or fracture, (2) use of ofloxacin antibiotics, (3) increased time between 
heart transplantation and initiation of quinolone treatment for infectious disease, 
(4) moderate alcohol use, (5) training during cold weather, (6) decreased isokinetic 
plantar flexor strength, (7) abnormal gait pattern with decreased forward progression 
of propulsion, (8) more lateral foot-roll over at the forefoot flat phase and (9) a 
creatinine clearance of <60 mL/min in heart transplant patients.16 17 19 22 24 25
Although other potential risk factors such as body weight or BMI, static foot posture 
measurements and physical activity level are often said to be risk factors in clinical 




Our systematic review indicates that for AT prevention and treatment the advice to 
patients might include: (1) to reduce the use of alcohol to less than 7 units per week 
for men and less than 4 for women, (2) to avoid the use of ofloxacin if alternatives 
are available and (3) to improve plantar flexor strength by performing strengthening 
exercises of the calf muscles.16 17 25 
Whether these interventions will be effective is unknown. For example, calf muscle 
exercises seem a plausible preventive intervention as decreased plantar flexor 
strength is a risk factor. However, eccentric calf muscle exercises did not decrease AT 
incidence in soccer players in a randomised trial.72 Further research is needed before 
we can state whether the logical interventions work or not.
Abnormal gait pattern with decreased forward progression of the propulsion and 
a more lateral foot-roll over at the forefoot flat phase were found to be risk factors 
for AT in novice runners. Van Ginckel et al. stated that more research is needed to 
confirm these findings, since this gait pattern with a decreased forward progression 
might be commonly used in well-trained athletes to improve gait economy.73 Since 
the gait pattern was determined barefoot, it is also not known whether these findings 
can be extrapolated to the running population, as running shoes might alter running 
gait.19 Biomechanical characteristics in AT are discussed in more detail in a recent 
systematic review.74
Previous research showed the relationship between BMI, body weight or waist 
circumference and tendon pathology.75 The hypothesis of this relationship is primarily 
based on the fact that the absolute tendon load is increased and that increased 
cytokine levels (Prostaglandin E2, tumour necrosis factor- α and Leukotriene B4) 
cause low-grade inflammation in obese individuals.76 77 In our systematic review, 
we were not able to find an association between being overweight and AT.16-19 22 23 
It should be noted that more than half of the cohort studies that investigated BMI 
as a risk factor were in adolescent populations, in which being overweight is less 
common.78 Arnoczky and colleagues hypothesised based on an animal model that 
being underweight is associated with AT, as a consequence of a catabolic state 
causing a decreased collagen production.79 This could lead to a U-shaped relationship 
for the BMI and AT, making it less likely that an association be found.80 More cohort 
studies are needed in heterogeneous populations. 
Another striking finding is the limited evidence for the absence of an association 
between physical activity level and AT. Inconclusive results regarding physical activity 
level were previously also demonstrated in patellar tendinopathy.81 In the majority 
of the scientific literature, tendinopathy is described as ‘overuse injury’. It could be 
that ‘overuse’ or ‘physical activity level’ is not measured accurately enough to detect 
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associations. It could also be hypothesised that a sudden change in load is more 
important than the absolute load that is currently being measured in studies. To date, 
there is, however, no convincing evidence that AT is a result of overuse.
Moderate alcohol use and increased time between heart transplantation and initiation 
of quinolone treatment for infectious disease were potential risk factors for AT.17 24 It is 
hard to hypothesise why these determinants are risk factors for AT. They might be a 
confounding factor, with lifestyle factors that influence AT risk. Another reason might be 
that these findings have been detected by chance. When a high number of analyses are 
performed, the chance of statistical significance findings increases. Adequate statistical 
methods can prevent possible coincidental findings. Another potential risk factor 
that is lacking a clear explanation is training during cold weather.22 The direct cause-
relationship is not known, as the results might be influenced by temperature or type of 
surface. This particular study did not report information on the temperature or training 
surface during the training period. These results are therefore difficult to extrapolate. 
Research implications
Our review showed that the majority of potential risk factors have only been 
investigated in cohort studies with a low number of cases (median 18 cases). Professor 
Roald Bahr and colleagues demonstrated that 20-50 cases are needed to detect 
moderate to strong associations and even 200 cases to detect small to moderate 
associations.82 Therefore, most studies in this review are likely to be underpowered 
to detect associations. Sample sizes in future studies should therefore be considered 
carefully. Future studies should also distinguish insertional from midportion AT, since 
these are two separate entities. It has been suggested that compression forces due 
to the bony prominence of the calcaneus play a role in the development of insertional 
AT, while this does not occur in midportion AT.4 Combining these entities, as occurred 
in most studies, is not ideal. 
There are several interesting determinants found in the cross-sectional studies for 
future research. Use of oral contraceptives and hormone replacement therapy were 
more common in patients suffering from AT.38 Only one research group investigated 
these factors; therefore, more research is needed to confirm these findings. 
Regarding lipid profile, Dr Jamie Gaida and colleagues reported that triglyceride level, 
triglyceride/high-density lipoprotein cholesterol ratio and apolipoprotein B were 
elevated in patients with AT.34 Hypertension prevalence was found to be increased in 
females in the study by Holmes and Lin, suggesting a possible relationship between 
blood flow circulation to the Achilles tendon and AT.38 However, all of these factors 




Genetic profiling is also a major topic in AT. Since 2002, 16 cross-sectional studies 
have evaluated the presence of genetic variations in AT.26 29 33 37 39 44-49 51-55 These genetic 
variations are linked to collagen structure, tendon or matrix homeostasis, apoptosis or 
inflammation pathways.8 This type of research provides more information regarding 
the biological pathways of the disorder. Future therapy strategies could focus on 
targeting these pathways.
Strengths and limitations
The strength of this systematic review is that we performed this structured analysis 
according to the PRISMA guidelines.71 Consequently, we were able to include 10 
cohort studies, whereas a different systematic review on this topic only included 1 
cohort study.8 That recent systematic review provided an excellent overview of all the 
literature considering genetic variants in AT, but important publications considering 
non-genetic risk factors in AT were missing. By including these cohort studies, our 
methods provide evidence that can be used directly in a clinical setting. We were 
also able to present an overview of topics on which future research should focus. 
Despite our robust research design, there are also methodological limitations. First, 
we only selected publications written in the English language. Second, we were not 
able to pool data because of the heterogeneity. The strength of the associations 
could therefore only be evaluated with a best evidence synthesis and not with meta-
analysis. Third, we chose to use a standardised set of criteria based on modified 
questions of existing quality assessment tools. This was recommended by Hayden et 
al., since no validated tools are available for systematic reviews on risk factors.83 Our 
tool used strict criteria, primarily considering clinical examination as valid outcome 
measure (criterion 6). Four cohort studies did not meet this criterion of which three 
of these studies used International Statistical Classification of Diseases and Related 
Health Problems (ICD) codes/search terms.17 24 25 The fourth study examined only 
runners with serious symptoms.20 These approaches to case-finding creates a bias. 
Furthermore, if this criterion would not be taken into account, the studies would still 
be considered to be of high risk of bias based on the other criteria. Fourth, the median 
age of the included cohort studies was 21 years due to the profession of most of the 
populations investigated. This is a relatively young age, since the mean age to develop 
AT is 30-60 years and AT is therefore expected to be less common in these studies.69
Conclusion
There is a lack of high-quality prospective studies investigating risk factors for AT. We 
found limited evidence for nine determinants as risk factor for Achilles tendinopathy: 
a history of lower limb injury, season of training, calf muscle strength, gait analysis 
parameters, moderate alcohol use, fluoroquinolone antibiotic treatment and 
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suboptimal renal function in a specific heart transplant population. Research funding 
agencies should prioritise research into modifiable determinants as these could 
prove useful for AT prevention and treatment. Quality studies will use valid clinical 
examination (focal Achilles tendon pain in relation to load with impaired load-bearing 
capacity) as outcomes, valid and reliable risk factor measurements and adequate 
statistical analysis in heterogeneous populations.
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Objectives: Ultrasound assessments of patients with chronic midportion Achilles 
tendinopathy include determining the degree of neovascularization using Doppler 
flow. A frequently used measure to quantify neovascularization is the modified Öhberg 
score. It is unknown whether the semiquantitative modified Öhberg score (0–4+) has 
higher reliability than a quantified measure of Doppler flow (0–100%). The purpose of 
this cross-sectional study was to evaluate the interobserver reliability of the modified 
Öhberg score and a surface area quantification (SAQ) method for Doppler flow in 
patients with chronic midportion Achilles tendinopathy. 
Methods: Two observers examined the degree of Doppler flow independently using 
SAQ and the modified Öhberg score during a single consultation. The intraclass 
correlation coefficient, standard error of measurement, and minimal detectable 
difference were determined to evaluate the reliability and measurement properties 
of the SAQ method and the modified Öhberg score. 
Results: In total, 28 consecutive patients with chronic midportion Achilles tendinopathy 
participated. The intraclass correlation coefficient for interobserver reliability of the 
SAQ method was 0.81 (95% confidence interval, 0.58–0.91), compared to 0.64 (95% 
confidence interval, 0.45–0.81) for the modified Öhberg score. The standard error of 
measurement and minimal detectable difference values for the SAQ method were 
2.9% and 8.0%, respectively, and for the modified Öhberg score, they were 0.55 and 
1.53 points. 
Conclusions: The SAQ method shows good reliability to evaluate the degree of 
Doppler flow in patients with chronic midportion Achilles tendinopathy, and it 
overcomes the ceiling effect of the modified Öhberg score. Future research should 
focus on the relationship between the SAQ method and clinical outcomes and use 




Chronic midportion Achilles tendinopathy (AT) is a degenerative condition of the 
Achilles tendon that most often occurs in running sports.1-3 Up to 52% of running 
athletes have AT at least once in their lifetimes.1 The clinical diagnosis AT is based on 
a combination of local Achilles tendon pain, swelling of the Achilles tendon, and an 
impaired load-bearing capacity.4 5 
Ultrasound (US) is frequently used to verify the diagnosis of AT. One of the features 
that have been reported in a substantial number of articles is the prevalence of US 
Doppler flow. Ultrasound Doppler flow indicates neovascularization, which is the 
formation of new small blood vessels within and around tendons.6 This process is 
driven by the production of vascular endothelial growth factor, which also stimulates 
nerve growth alongside the neovascularization.7 8 It is hypothesized that these 
newly formed nerve structures are a contributor or the cause of the pain in chronic 
tendinopathy.6 Since these nerve structures cannot be visualized with US, US Doppler 
flow is being used as a marker for the amount of newly formed nerve structures.
Increased US Doppler flow can be determined by both colour Doppler ultrasound 
and power Doppler ultrasound (PDUS). Power Doppler ultrasound is the preferred 
method to use, since it is more sensitive to detect blood flow and is less operator 
dependent.9 Increased Doppler flow is present in 47% to 100% of symptomatic 
Achilles tendons compared to 0% to 50% of asymptomatic tendons.6 10-18 Most of the 
studies used the modified Öhberg score to quantify the amount of Doppler flow, 
which has shown higher reliability compared to the original Öhberg score.19 The 
modified Öhberg score runs from 0 to 4+.4 20 A higher score indicates more Doppler 
flow in the peritendinous and intratendinous tissues.
The interobserver reliability of the modified Öhberg score varies from moderate to 
perfect 10 12 19. Some studies described other disadvantages of the modified Öhberg 
score. It is considered to have weak applicability to measure higher amounts of Doppler 
flow (called the ceiling effect), and the scoring system is operator dependent, since 
the assessment of the score is difficult.11 20 To make the assessment less difficult, it has 
been suggested to reduce the modified Öhberg score to a 4 -point scale by combining 
the 3+ and 4+ categories.10 12 This will, however, further increase the ceiling effect of 
this method. Therefore, reliable alternatives for the modified Öhberg score with a 
quantitative approach are warranted. The surface area quantification (SAQ) method 
was introduced by Boesen et al. to overcome these limitations and has been used by 
several other research groups.21 22 This method aims to determine the percentage 
of colour pixels within the Achilles tendon, the peritendinous region, or both. This 
enables a more quantitative analysis and potentially increases the accuracy of the 
measurement in a research setting. As the analysis is directly accessible and easy to 
perform, implementation in the clinical setting would also be feasible if medical device 
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manufacturers were to implement this method as a real-time application on their US 
machines. Both previous studies that investigated the SAQ method standardized the 
colour Doppler settings for all examinations to increase reliability.21 22 The reliability 
of such a standardized method is, however, currently unknown because previous 
studies did not assess reliability measures.
Our primary aim was to compare the reliability of the SAQ method with the modified 
Öhberg method in patients with AT by determining the intraclass correlation coefficient 
(ICC) between 2 observers. We hypothesized that the ICC of the SAQ method would 
be considerably higher compared to the semiquantitative modified Öhberg method. 
Secondary aims were (1) to evaluate the correlation between both methods to 
test whether the same feature (amount of Doppler flow) was being measured and 
(2) to evaluate the standard error of measurement (SEM) and minimal detectable 
differences (MDD) of these methods.
Methods
Study design 
This cross-sectional study was conducted as a part of an ongoing double-blind, 
placebo-controlled randomized clinical trial (RCT). The aim of this RCT was to 
evaluate the effect of a high-volume injection in patients with chronic midportion AT 
(ClinicalTrials.gov identifier NCT02996409). Written informed consent was obtained 
before participation for all patients and also for the cross-sectional part of this study. 
The protocol of the study was approved by the regional Medical Ethical Committee 
(registration number 14-100). 
Setting and participants 
This cross-sectional study was performed at the Department of Sports Medicine in 
a large district general hospital (The Hague Medical Centre). The first 32 consecutive 
included patients who participated in the RCT were asked to take part in this cross-
sectional study from April 2017 to November 2017. Inclusion criteria were: (1) the 
presence of a chronic midportion AT for at least 2 months, (2) the completion of an 
exercise training program for at least 6 weeks with an unsatisfactory outcome, (3) age 
between 18 and 70 years, and (4) the presence of Doppler flow on PDUS imaging. 
The diagnosis was established on the basis of a clinical examination (local tendon 
pain, swelling of the Achilles tendon 2–7 cm proximal to its calcaneal insertion, and 
an impaired load-bearing capacity) by a physician with experience in sports medicine 
(15–20 years). As AT is considered a clinical diagnosis in principle, grayscale US was 
not used to verify the diagnosis.3 Main exclusion criteria were: (1) a clinical suspicion 
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of other musculoskeletal disorders (insertional AT, inflammatory systemic disorders, 
and quinolone-, corticosteroid- or statin-induced tendinopathy), (2) a previous Achilles 
tendon rupture or surgery, (3) the inability to perform an exercise program, and (4) a 
medical condition that would affect the safety of the injection (eg, peripheral vascular 
disease or the use of anticoagulant medication). Detailed information regarding all 
exclusion criteria is provided in the trial registration. In cases of bilateral symptoms, 
only the most affected tendon was included in the study. 
Test methods 
Demographic details 
Demographic characteristics of the study population were collected at baseline. We 
collected the following characteristics: age, sex, body mass index (BMI), duration of 
symptoms, Victorian Institute of Sport Assessment – Achilles (VISA-A) score, primary 
sport, and activity level. The VISA-A questionnaire consists of 8 questions and covers 
3 domains: pain, activity, and function. Scores vary from 0 to 100, where 100 indicates 
an asymptomatic person, and 0 is defined as maximum pain, no activity, and no 
function. The activity level was determined by the researcher as recreational (1 or 2 
sports activities per week), competitive (≥3 sports activities per week), or professional 
(≥3 sports activities per week at a national level).
Ultrasound
Two observers analysed the Achilles tendons of the included patients independently 
during a single consultation. The PDUS was performed by 1 observer, while the other 
observer was not present in the room to maintain blinding. Both observers (1 PhD 
candidate [A.C.v.d.V.] and 1 research student (J.M.V.]) were trained to perform US 
measurements of the Achilles tendon with greater than 20 training hours and at least 
10 patients before the start of the study. Ultrasound examinations for this study were 
performed during one of the follow-up visits after inclusion in the RCT. Before the US 
examination was performed, all patients climbed 2 stairs to reach the examination 
room. No specific instructions were provided about activities before the consultation 
(eg, sports activities the day before). The patient was placed in a prone position on the 
examination table, and the ankle was placed over the table in a relaxed position. A Pro 
Focus type 2202 US scanner (BK Medical, Herlev, Denmark) with a type 8811 5–12-
MHz linear transducer was used to perform US measurements. Neovascularization 
was detected by PDUS with predefined settings: mechanical index, 1.28; thermal 
index, 1.2; pulse repetition frequency, 1.0 kHz; and gain, 50%. These settings were 
determined before the start of the study according to the optimization suggestions 
by Yang et al.9 Depth was standardized for every patient at 3.0 cm, and the colour 
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box size during the PDUS examination at 4.6 cm2 (depth, 1.7 cm; width, 2.7 cm). This 
colour box size was chosen to measure the maximum intratendinous Doppler flow 
and peritendinous flow in the Kagers’ triangle. Peritendinous flow was included to 
assess the same regions of interest for both the modified Öhberg score and the SAQ 
method. 
The transducer was placed perpendicular to obtain a sagittal view of the Achilles 
tendon at the most painful part on palpation. The upper limit of the colour box 
was placed on the dorsal side of the tendon. Pressure from the transducer was 
kept to a minimum to prevent occlusion of neovascularization.16 23 Both observers 
screened the tendon for the area of maximum Doppler flow during the preparation 
phase for 1 minute. The transducer was gently moved to medial and lateral over 
the area where Doppler flow was present. When the location of maximum Doppler 
flow was identified, a 20-second video was recorded. The modified Öhberg score was 
determined dynamically during the US examination according to previous studies.10 
16 24 When the first observer completed the US examination, the second observer 
directly performed the examination to keep the time between the examinations to a 
minimum. The patient remained in the same prone position and was blinded to the 
outcome of the first observer to standardize for possible confounders.
Analysis using SAQ 
We used Kinovea (Bordeaux, France) software to observe the PDUS video in steps of 
0.04 seconds to obtain 3 frames with visually maximum Doppler flow. To measure 
the surface area of the Doppler flow, we used the program ImageJ version K 1.45 
(National Institutes of Health, Bethesda, MD). The area directly around the colour 
box was selected, and the outer part was cleared. Predefined transformations 
were applied in this study to limit the noise close to 0: threshold colour, black and 
white; hue, 255; saturation, 165; and brightness, 250. After transformation, colour 
pixels of blood vessels were shown as white pixels with a value of 255, and noncolor 
pixels were shown as black pixels with a value of 0. The number of white pixels was 
subsequently determined by creating a pixel histogram. The number of white pixels 
was divided by the total number of pixels in the colour box (99,119 pixels) to measure 
the percentage of displayed blood vessels. This percentage was determined for the 3 
frames, and the highest percentage was selected for the analysis. The transformation 
of the Doppler flow using the SAQ method is illustrated in Figure 1. Both observers 




Figure 1. Left, Colour box during PDUS of a patient with chronic midportion AT in a sagittal 
view. Right, Same colour box after transformation of colour pixels to white pixels to make SAQ 
possible.
 
Analysis using the modified Öhberg score
The modified Öhberg score is a 5-point grading scale to score neovascularization in 
various types of tendinopathy: 0 indicates the absence of Doppler flow; 1+ indicates 1 
or 2 neovessels in the Kagers’ fat pad; 2+ indicates 1 or 2 intratendinous neovessels; 
3+ indicates 3 or 4 intratendinous neovessels; and 4+ indicates a network of 
neovascularization with more than 5 intratendinous neovessels.10 16 24 
Statistical analyses 
Both researchers imported data from the measurements they performed themselves. 
The normality of the data was checked visually with Q-Q plots and statistically with 
the Shapiro-Wilk test. The correlation between the degree of Doppler flow measured 
by the SAQ method and modified Öhberg score was analysed with the Spearman 
correlation coefficient. The Spearman correlation coefficient was interpreted as a 
scale from poor to almost perfect correlation (<0.00, poor; 0.00–0.20, slight; 0.21–0.40, 
fair; 0.41–0.60, moderate; 0.61–0.80, substantial; and 0.81–1.00, almost perfect).25 
The interobserver reliability of both methods was analysed first by determining 
the Spearman ρ correlation coefficient for non–normally distributed data and the 
Pearson ρ correlation coefficient for normally distributed data. Correlations were 
controlled visually by constructing a scatterplot. The ICC for interobserver reliability 
was determined by the 2-way random-effect model with absolute agreement. 
Interpretation of the ICC was as suggested by Portney and Watkins; values of less 
than 0.5 indicate poor reliability; scores between 0.5 and 0.75 indicate moderate 
reliability; and scores of greater than 0.75 indicate good reliability.26 In addition, the 
SEM and MDD were determined for both methods by the following equations: 27 28 
 SEM = !(MSw) 
 




Where MSw represents the within-subject mean square derived from the analysis of 
variance. We used SPSS Statistics version 24.0 software (IBM Corporation, Armonk, 
NY) to analyse data, and statistical significance was set at α = .05 (2-tailed). Additionally, 
we determined the prevalence- and bias-adjusted κ for ordinal data (PABAK-OS) for 
the modified Öhberg score using a Web-based PABAK-OS calculator (http://www. 
singlecaseresearch.org/calculators/pabak-os). We performed this test to adjust for 
chance agreement of the ordinal modified Öhberg score, since the ICC is designed to 
be used for continuous outcomes. Using the PABAK-OS, we were able to determine 
whether it was justified to determine the ICC for the modified Öhberg score.29 
Results
Patient characteristics 
Of the first 32 consecutive patients who were included in the RCT, 4 patients did not 
participate in this cross-sectional study. Two patients were lost to follow-up in the RCT, 
and 2 patients declined to participate in this study part (lack of time). Consequently, 
28 patients participated in this cross-sectional study, which was performed during 
follow-up of the RCT. The mean population age was 49.6 years (range, 35–59 years), 
and the median symptom duration was 56 weeks (range, 10–1040 weeks). The mean 
VISA-A score at baseline was 42.8 points (range, 9–73 points). Detailed baseline 
demographic characteristics are presented in Table 1. 
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Table 1: Demographic baseline characteristics of the study population (n=28)




Body Mass Index, mean ± SD, kg/m2 26.3 ± 5.0 




Duration of symptoms, median (IQR), weeks 56.0 (10.0-104.0)
VISA-A score, mean ± SD 42.8 ± 15.0







Tai Bo 1 (3.6%)
Shooting archery 1 (3.6%)
Hiking 2 (7.1%)
No sports 2 (7.1%)




SD: standard deviation, IQR: interquartile range, VISA-A: Victorian Institute of Sport Assessment 
– Achilles (measured at baseline)
Ultrasound assessments 
The mean colour fraction of the SAQ method ranged from 9.0% to 10.9% for both 
observers (mean ± SD: observer 1, 9.0% ± SD 6.6%; observer 2, 10.9% ± SD 6.8%). The 
lowest observed colour fraction was 0.4%, and the highest was 27.2%. The median of 
the modified Öhberg score (0–4+) ranged from 3.0 to 3.5 for both observers (observer 
1, 3.0 [interquartile range, 1.0]; observer 2, 3.5 [interquartile range, 2.0]). The range 
was 1+ to 4+ for both observers. 
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Correlation between the SAQ method and modified Öhberg score 
The Spearman correlation coefficient between the SAQ method and the modified 
Öhberg score showed a substantial correlation for both observers. The correlations 
were found to be 0.76 for observer 1 and 0.62 for observer 2. The SAQ outcomes for 
the modified Öhberg 4+ group ranged from 5.5% to 27.1% for observer 1 and from 
5.2% to 27.2% for observer 2 (Figure 2). 
Figure 2. Scatterplot showing the correlation between the modified Öhberg score and SAQ. Note 
the ceiling effect in the Öhberg 4+ group, in which the SAQ ranges between 5.2% and 27.2%.
Intraclass correlation coefficient for interobserver reliability 
The ICC of the SAQ method was found to be 0.81 (95% confidence interval [CI], 
0.58–0.91), whereas it was 0.64 (95% CI, 0.35–0.81) for the modified Öhberg score. 
The ICCs, SEMs, and MDDs are reported in Table 2. The PABAK-OS for the modified 
Öhberg score was found to be 0.33 (95% CI, 0.17–0.50). 
Table 2: Intraclass correlation coefficients of the Surface Area Quantification (SAQ) method 
and modified Öhberg score
Correlation (95% CI) P-value SEM MDD n
ICC SAQ method 
(0-100%)
0.81 (0.58-0.91) <0.001 2.88% 7.99% 28
ICC modified 
Öhberg score (0-4 
points)
0.64 (0.35-0.81) <0.001 0.55 points 1.53 points 28
The correlation for an individual measurement method was significant below the .05 level (2 tailed). Note that 
the SAQ method ranges from 0% to 100%, and the modified Öhberg score ranges from 0 to 4+ points. The 
SEM and MDD are therefore presented as a percentage for the ICC of the SAQ method and as a number for 




To our knowledge, this was the first study to investigate the reliability of the SAQ 
method in midportion AT and to compare it with the most widely used quantification 
method (modified Öhberg score). We showed that the SAQ method is a reliable 
measurement tool in a research setting to evaluate the degree of US Doppler flow in 
patients with chronic midportion AT. According to our findings, the SAQ method is not 
superior to the modified Öhberg score for quantifying neovascularization. There are, 
however, advantages to the SAQ method, since it is a more quantitative method and 
overcomes the ceiling effect of the modified Öhberg score by differentiation between 
high amounts of Doppler flow. 
Surface area quantification is a method to quantify the fraction of colour pixels during 
a PDUS examination. We found good interobserver reliability for the SAQ method 
(ICC, 0.81) compared to moderate interobserver reliability for the modified Öhberg 
score (ICC, 0.64).
Similar findings for the ICC of the modified Öhberg score were published by Risch et al, 
in which moderate absolute interobserver agreement (0.64–0.80) was also observed.19 
Sengkerij et al and Watson et al observed considerably higher ICCs for the modified Öhberg 
score (0.85 and 0.86, respectively).10 12 In all studies, measurements were determined 
by experienced radiologists or sports and exercise medicine consultants. One major 
difference between the studies was that the modified Öhberg scores were determined 
on the basis of US recordings in the study performed by Risch et al, whereas the US 
examinations were performed by the observers themselves in the other 2 studies. This 
indicates that agreement between observers is not dependent solely on the experience 
of the observer performing the US examination but also on the observer interpreting the 
findings. Since the SAQ method selects multiple frames with visually maximum Doppler 
flow and provides an objective percentage for the colour fraction, interpretation of the US 
recordings that can cause interobserver variability will play a minor role. 
We have demonstrated that there is a substantial correlation between the SAQ method 
and the modified Öhberg score (Figure 2). A perfect correlation was not expected, 
since the modified Öhberg score is limited to a maximum score of 4, whereas the 
SAQ method can detect any amount of Doppler flow. The modified Öhberg score 
is therefore less applicable when there is a high degree of Doppler flow present, as 
the modified Öhberg 4+ subgroup will represent a wide variation in the degree of 
Doppler flow. This is called the ceiling effect, in which an extra amount of Doppler 
flow no longer has an effect on the Öhberg score. This ceiling effect was shown in our 
study for the modified Öhberg 4+ group (range for the SAQ method, 5.2%–27.2%). 
This could also be an explanation of why the degree of Doppler flow is to date only 
weakly related to clinical severity, and future research should therefore focus on the 
correlation between the SAQ measurement and clinical severity.13 15 18 
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The ICC does not provide a measure of the precision: ie, the difference in individual 
patients. The precision of a measurement can be determined by calculating the SEM, 
which reflects the boundaries around the true score of the individual and is largely 
independent of the variance between patients.28 The SEM for the SAQ method was 
2.9% in this study. This indicates that when a colour fraction of 11.0% is be found, 
the true value of the observation would be between 8.1% and 13.9%. It is difficult to 
compare this SEM with the SEM of the modified Öhberg score, since this is an ordinal 
score ranging from 0 to 4+, whereas the SAQ method ranges from 0% to 100%. The 
SEM of the modified Öhberg score was 0.55. An observed Öhberg score of 2 would 
therefore have a true value between 1.45 and 2.55. 
The MDD is calculated from the SEM and reflects the threshold for the change 
within a patient that can be considered a real change.28 This is relevant to determine, 
since these kind of quantification methods will be primarily used during follow-up to 
monitor treatment responses. The MDD for the SAQ method was found to be 8.0%. 
This indicates that in the same patient with a colour fraction of 11.0%, a value of less 
than 3.0% or greater than 19.0% during follow-up would indicate a real decrease or 
increase in the colour fraction, respectively. The MDD of the modified Öhberg score 
was found to be 1.5. When an observed Öhberg score of 2 is found in a patient, 
a value of less than 0.5 or greater than 3.5 during follow-up would indicate a real 
change. 
Limitations
This study had some methodological limitations. First, we chose a standardized size 
of the colour box to only detect intratendinous and peritendinous neovascularization 
in the Kagers’ fat pad in most of the patients. In a case of a relatively small Achilles 
tendon, deeper structures such as the posterior tibial artery tibialis could be included 
in the colour box. The presence of this artery was not discussed in the standardized 
protocol. There was 1 patient in whom this artery was present, and a single observer 
measured the artery in contrast to the other observer. Determination of the modified 
Öhberg score was not affected by the presence of the artery in this case. The 
reliability of the SAQ could potentially be further improved if the posterior tibial artery 
is recognized and not included in the colour box during the US examination. We think 
that adding this to the SAQ protocol is most appropriate, since the posterior tibial 
artery is part of the normal vascular structure, and it is not a result of the process 
of neovascularization. Second, we have not determined intraobserver reliability. In 
patellar tendinopathy, it was previously demonstrated that day-to-day variability in 
Doppler flow is present; however, in midportion AT, it was shown that the intraobserver 
reliability of the modified Öhberg score was excellent.19 30 Future research should 
investigate the intraobserver reliability of the SAQ method to verify the diagnostic value 
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of SAQ. Third, ideally a minimum of 3 observers would be involved in a reliability study, 
since a lack of variability would increase the ICC. We have, however, demonstrated 
that the SEM indicates fairly good precision. The SEM is, contrary to the ICC, largely 
independent of variation between patients. We therefore expect that the use of this 
method would be valid in future research projects. Fourth, US measurements were 
performed by relatively inexperienced sonographers (1 PhD candidate and 1 research 
student). Our results demonstrated that the SAQ method is less operator dependent 
and therefore can be performed well after some practice. Fifth, since the modified 
Öhberg score is an ordinal scale, the ICC (designed for continuous scales) is not the 
most appropriate measure for expressing reliability. Therefore, we determined the 
PABAK-OS to control for the fact that the chance of agreement is higher in an ordinal 
scale compared to a continuous scale. We have demonstrated that the PABAK-OS 
was indeed lower for the modified Öhberg score, indicating that the ICC does not 
overestimate the reliability of the modified Öhberg score. Sixth, we chose to refrain 
from a power analysis, since data for this novel measurement tool were not available 
when designing this study, and post hoc power analyses are discouraged.31 Last, the 
SAQ method is currently not available as a measurement function on US machines, 
and computers and (free) software packages have to be used to determine the value 
of the SAQ. Since we used a relatively easy method to calculate the value of the SAQ, 
we expect that this function could be implemented easily on US machines via a real-
time application once it has shown its clinical relevance in future studies through 
estimating the prognosis or personalized treatment based on SAQ scores. 
Conclusion
To our knowledge, this was the first study to evaluate the diagnostic value and reliability 
of measuring the surface area of Doppler flow in patients with chronic midportion 
AT. This study demonstrates that SAQ has similarly good reliability as the modified 
Öhberg score. Surface area quantification, however, overcomes disadvantages of 
the modified Öhberg score, of which the ceiling effect in the modified Öhberg 4+ 
category is most important. These findings could inspire medical experts to use the 
SAQ method for research purposes to determine the degree of US Doppler flow 
quantitatively in patients with chronic midportion AT. Ultimately, treatment responses 
of interventions acting on neovascularization could be monitored quantitatively and 
with good reliability. More research is needed regarding the intraobserver reliability 
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Objective: To provide a consistently updated overview of the comparative 
effectiveness of treatments for Achilles tendinopathy.
Design: Living systematic review and network meta-analysis.
Data sources: Multiple databases including grey literature sources were searched up 
to February 2019. 
Study eligibility criteria: Randomised controlled trials examining the effectiveness 
of any treatment in patients with both insertional and/or midportion Achilles 
tendinopathy. We excluded trials with 10 or fewer participants per treatment arm or 
trials investigating tendon ruptures. 
Data extraction and synthesis: Reviewers independently extracted data and 
assessed the risk of bias. We used the Grading of Recommendations Assessment, 
Development and Evaluation to appraise the certainty of evidence. 
Primary outcome measure: The validated patient-reported Victorian Institute of 
Sport Assessment-Achilles questionnaire.
Results: 29 trials investigating 42 different treatments were included. 22 trials 
(76%) were at high risk of bias and 7 (24%) had some concerns. Most trials included 
patients with midportion tendinopathy (86%). Any treatment class seemed superior 
to wait-and-see for midportion Achilles tendinopathy at 3 months (very low to low 
certainty of evidence). At 12 months, exercise therapy, exercise+injection therapy 
and exercise+night splint therapy were all comparable with injection therapy for 
midportion tendinopathy (very low to low certainty). No network meta-analysis could 
be performed for insertional Achilles tendinopathy.
Conclusion: In our living network meta-analysis no trials were at low risk of bias and 
there was large uncertainty in the comparative estimates. For midportion Achilles 
tendinopathy, wait-and-see is not recommended as all active treatments seemed 
superior at 3-month follow-up. There seems to be no clinically relevant difference 
in effectiveness between different active treatments at either 3-month or 12-month 
follow-up. As exercise therapy is easy to prescribe, can be of low cost and has few 
harms, clinicians could consider starting treatment with a calf-muscle exercise 
programme. 




The incidence of Achilles tendinopathy is 2–3 per 1000 patients in general medicine 
practice, and its lifetime cumulative incidence can even increase to more than 50% in 
specific active populations (eg, runners).1 2 Achilles tendinopathy is an overload injury 
that is diagnosed clinically, and can affect the distal insertion or the midportion of the 
tendon.3 4 Managing tendinopathy is challenging. Patients can expect their symptoms 
to improve between 3 and 12 months after commencing treatment, but not beyond 
12 months.5 Chronic symptoms persist in approximately a quarter of patients 10 years 
after treatment, and tendinopathy impairs both quality of life and physical activity.5 6
Wait-and-see, exercise therapy, injections, shockwave therapy, orthosis, medication, 
and surgery are the main treatment options offered to patients with Achilles 
tendinopathy.7-14 Most patients receive multiple treatments over time, thereby 
impacting on healthcare consumption.15 Trials and conventional meta-analysis do 
not directly assess the relative effectiveness of all available treatments – challenging 
patients and clinicians when they make treatment decisions. Network meta-analysis 
(NMA) allows the simultaneous comparison of the effectiveness of all treatments, and 
can rank treatments from most to least effective.16 17 As no comprehensive NMA of 
all treatment options for Achilles tendinopathy exists, our aim was to evaluate the 
comparative effectiveness of all available treatments for Achilles tendinopathy in a 
regularly updated (‘living’) systematic review using NMA.
Methods
Protocol and registration
Our living systematic review with NMA was prospectively registered on PROSPERO 
(International Prospective Register of Systematic Reviews: CRD42018086467) and 
published in an open repository.18 We followed the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guideline, the Meta-Analysis of 
Observational Studies in Epidemiology guideline, and the PRISMA-NMA extension for 
reporting NMA.19-21
Administration and update of the living systematic review 
This systematic review with NMA is part of the Dutch multidisciplinary guideline for 
Achilles tendinopathy. As we (1) plan to update the search and review process every 
5 years as part of the guideline revision process, and (2) perform annual screening 
to identify new data that may alter the conclusions and recommendations,18 we 
defined this as a ‘living’ systematic review with NMA. A living systematic review’s main 
advantage is that it assumes that new knowledge will appear and allow improvements 
84
Chapter 5
in clinical decision-making. As we already have a structured protocol and database 
for this systematic review, we will be able to answer future research questions quickly 
and promote faster translation of new scientific evidence into clinical practice.
Patient involvement
To determine clinically relevant outcomes, we performed a pilot round of focus 
interviews with consecutive patients suffering from chronic midportion Achilles 
tendinopathy (n=9) who were participating in a randomised clinical trial (NCT02996409), 
and administered a survey to patients identified through the Dutch national patient 
federation (n=97).18 The results are presented in online supplementary web appendix 
1. We also considered recently defined core domains for tendinopathies from an 
international consensus involving patients and healthcare providers.22 Based on 
these data, we decided to evaluate clinical outcome with the validated and disease-
specific Victorian Institute of Sport Assessment-Achilles (VISA-A) score as the primary 
outcome.18 23 
Outcome measures
The VISA-A score quantifies pain and activity level and can range from 0 to 100; a score 
of 100 indicates no pain with full activity level, while a score of 0 indicates severely 
limited activity levels and severe levels of pain. The minimal important difference 
(MID) for the VISA-A score is 14 points.24 Return to sports activities was the secondary 
outcome. We assessed outcomes at 3, 6 and 12 months.
Eligibility criteria
Trials were eligible if they investigated the effectiveness of any treatment in adults 
(≥18 years) with Achilles tendinopathy, using the outcome measures VISA-A 
questionnaire and/or return to sports activities. Populations with midportion 
tendinopathy, insertional tendinopathy, or a combination of both were included. 
Achilles tendinopathy must have been diagnosed based on clinical findings (eg, local 
pain reproduced on clinical examination).25 Imaging to confirm the diagnosis was not 
an inclusion criterion. Trials including athletes and/or inactive patients were eligible. 
There were no language restrictions. 
Any treatment, control treatment, placebo, wait-and-see or no treatment group 
studied in a trial was eligible for inclusion. We predefined a number of treatment 
classes, based on the assumption that some treatments have a similar effect due to a 
comparable working mechanism.18 Table 1 shows the treatments that are subdivided 
into treatment classes. 
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Table 1. Assignment of treatments to classes
Treatments Studies Classes
Placebo-injection + eccentric 
exercises (high-dose)
Bell 2013, Boesen 2017, De 
Jonge 2011
Exercise therapy + placebo 
injection
Autologous blood injection + 
eccentric exercises (high-dose)
Bell 2013, Pearson 2012 Exercise + injection therapy
High-volume injection + 
eccentric exercises (high-dose)
Boesen 2017 Exercise + injection therapy
Platelet-rich plasma (PRP) 
-injection + eccentric exercises 
(high-dose)
Boesen 2017, De Jonge 2011 Exercise + injection therapy
Eccentric exercises (high-dose) Pearson 2012, Beyer 2015, De 
Jonge 2010, Silbernagel 2007, 
Yelland 2011, Rompe 2007, 
Rompe 2009, Zhang 2013, 
Balius 2016, Stevens 2014
Exercise therapy
Heavy slow resistance 
exercises
Beyer 2015 Exercise therapy
Night splint + eccentric 
exercises (high-dose)
De Jonge 2010 Exercise + night splint 
therapy
Continued sports activity + 
eccentric exercises (high-dose)
Silbernagel 2007 Exercise therapy
Prolotherapy injections Yelland 2011 Injection therapy
Prolotherapy injections + 
Eccentric exercises (high-dose)
Yelland 2011 Exercise + injection therapy
Shockwave therapy Rompe 2007 Shockwave therapy
Wait-and-see Rompe 2007 Wait-and-see
Shockwave therapy + eccentric 
exercises (high-dose)
Rompe 2009 Exercise + shockwave 
therapy
Acupuncture treatment Zhang 2013 Acupuncture therapy
Mucopolysaccharides 
supplement + eccentric 
exercises (high-dose)




supplement + passive 
stretching
Balius 2016 Exercise + 
mucopolysaccharides 
supplement therapy
Eccentric exercises as 
tolerated
Stevens 2014 Exercise therapy
We excluded trials with (1) 10 or fewer participants per study arm, (2) an inadequate control group (eg, the 
use of the contralateral Achilles tendon), (3) a population with full-thickness ruptures of the Achilles tendon, 
and (4) animal or in vitro studies. 
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Literature search strategy and information source
We developed a sensitive search strategy for multiple databases with the assistance 
of a medical librarian (online supplementary web appendix 2). The following 
databases were searched for published and unpublished trials up to 21 February 
2019: Embase, MEDLINE Ovid, Web of Science, Cochrane CENTRAL, CINAHL 
EBSCOhost, SPORTDiscus EBSCOhost, AMED EBSCOhost, WHO ICTRP, ClinicalTrials.
gov, WorldCat.org, OpenGrey and Google Scholar. We used the validated Cochrane 
search filter ‘Embase search strategy for finding randomised clinical trials in Embase’, 
and modified this for all conventional databases.26 We screened the reference lists of 
all included publications for potentially eligible trials. 
Study selection and data extraction
Titles and abstracts were screened by two independent reviewers (ACV and RJ-V) 
after duplicate removal. Disagreements were resolved by consensus. Two reviewers 
independently applied eligibility criteria to the full text reports. Disagreements were 
resolved by a third reviewer (AW). In case of unpublished records, authors were 
contacted for data availability. We uploaded all trials to Covidence (Veritas Health 
Innovation, Melbourne, Australia).
Data were extracted independently by two reviewers (ACV plus one of: AW, CLA or RJ-
V) using standardised extraction forms adapted from the Cochrane Collaboration.26 
Disagreements were resolved by consensus, or a fifth reviewer (MW) in case of 
persistent disagreement. We extracted publication and trial details, population 
characteristics, eligibility criteria, treatment details, relevant outcome information, 
details of analysis, and study authors’ key conclusions. If there were multiple time 
points available within a study, and these were equally close to the time point being 
synthesised across trials, we extracted the outcome of the latest follow-up for 
analysis.18
Risk of bias assessment
We used the Risk of Bias 2 tool to assess risk of bias for each trial outcome.27 We 
assessed risk of bias on the basis of ‘assignment to intervention’ for all five domains: 
(1) randomisation process, (2) deviations from intended interventions, (3) missing 
outcome data, (4) outcome measurement and (5) selection of the reported result. 
An overall risk of bias judgement was made for each outcome and each time point as 
either ‘low risk’, ‘some concerns’ or ‘high risk’ of bias.28 29
The assessment was performed independently by two reviewers (ACV plus one of 
MW, CLA, AW or R-JV). The reviewers did not perform risk of bias assessment or data 
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extraction for publications in which they were involved as author. Disagreements 
were resolved via consensus or by a third reviewer (MW or AW) if necessary. 
Data synthesis and statistical methods
We constructed network plots using Stata V.15 to visualise all head-to-head 
comparisons. Eccentric exercises were labelled as high-dose (daily) or low-dose 
(less than once a day). We planned a time course analysis for the VISA-A score; 
however, insufficient data precluded the analysis.18 Instead, we modelled networks 
for the primary and secondary outcomes at 3 months, 6 months and 12 months, 
where possible. Four reviewers (ACV, MW, AW, and R-JV) labelled the treatments and 
assigned them to categories (classes) (see table 1). We assessed the assumption of 
exchangeability required for NMA before commencing the analyses. We appraised 
clinical homogeneity by tabulating study and population characteristics and inspecting 
them for differences in effect modifiers.
Treatment-level and class-level models were fitted in a Bayesian framework using 
Markov chain Monte Carlo simulations in WinBUGS (V.1.4; Medical Research Council, 
UK, and Imperial College of Science, Technology and Medicine, University of Cambridge, 
UK).17 30 Continuous outcomes are presented as mean difference, with their 95% 
credible intervals. We reported the mean, median and 95% credible intervals for the 
ranking of each treatment or class to estimate the likelihood of individual treatments 
being superior to other treatments, and interpreted the primary outcome results in 
light of the MID. 
For both treatment-level and class-level models, we fitted fixed and random effects 
models, and compared model fit using the deviance information criterion and 
posterior mean residual deviance.17 Lower deviances depict a better model fit. For the 
class-level models we attempted to fit a hierarchical model where treatment effects 
were assumed to be similar within class, but due to insufficient data we were only able 
to fit a fixed class effect model where all treatments were assumed to have the same 
effect within class. 
We assessed statistical heterogeneity by inspecting the between-trial SD and 
comparing the fit of the fixed and random effects models.17 We planned to explore 
sources of statistical heterogeneity if there were 10 or more trials available per 
comparison. In the presence of evidence from direct and indirect comparisons 
it is important to assess whether the direct and indirect evidence is consistent.31 
We assessed the consistency assumption for each network by comparing model 
fit between the NMA model and an unrelated mean effects model that relaxes the 
consistency assumption. We planned to assess small study bias using comparison-




We used the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) for NMAs to appraise the certainty of evidence.32 Evidence from 
each comparison was appraised for direct and indirect comparisons, and for the 
combined evidence, where applicable. Evidence could be of ‘high certainty’, ‘moderate 
certainty’, ‘low certainty’ or ‘very low certainty’. All ratings started at the level of ‘high 
certainty’. Two authors (ACV and MW) independently rated the evidence down on 
the basis of risk of bias, inconsistency, indirectness, imprecision and publication bias. 
Inconsistency in GRADE involves heterogeneity across trials and is not related to 
inconsistency in the network. We rated the overall body of evidence in the network to 
indicate the strength of the NMA recommendations. 
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Figure 1. PRISMA flow diagram of study selection process. IPD, individual patient data; LPLV, 





We identified 5,154 potentially relevant publications, of which 170 articles were 
screened in the full-text analysis. Twenty-nine trials (n=1,640 patients) met our 
eligibility criteria and were included (figure 1).33-61 Online supplementary web appendix 
3 lists the 14 unpublished trials and the 3 trials awaiting classification. 
Characteristics of the included trials
Forty-two treatments were investigated in 29 trials. Sixty-five treatment arms were 
included in the trials, and 40 of these included exercise therapies. There were 
180 treatment comparisons in the NMAs. The majority of trials (86%) investigated 
midportion Achilles tendinopathy, one investigated insertional Achilles tendinopathy 
and three trials did not specify the location of Achilles tendinopathy. Twenty-five trials 
evaluated clinical outcome using the VISA-A score and six trials reported return to 
sports activities. Sample sizes ranged from 12 to 117 per treatment arm (median 
20 patients, IQR 16–27). Follow-up duration ranged from 1 to 52 weeks (median 27 
weeks, IQR 12–52). 
The baseline characteristics of patients and all trial characteristics are shown in online 
supplementary web appendices 4 and 5. Study populations reflect clinical practice 
with equal sex distribution, participants in their 40s and slightly overweight. Three-
quarters of the included participants were active individuals. Participants typically 
had symptoms for nearly 2 years prior to treatment; approximately 20% had bilateral 
symptoms. The severity of symptoms measured with the VISA-A score was usually 
between 40 and 60 points.
Risk of bias and certainty of evidence
Twenty-two trials (76%) were at high risk of bias (online supplementary web appendix 
6). We had some concerns about bias in seven trials (24%). No trials were at low risk 
of bias. In studies that used both the VISA-A score and return to sport as outcome 
measures, there was no difference in risk of bias between the outcomes. In 48% of 
the trials, outcome measurement was a source of bias. All other sources of bias were 
also commonly judged as high risk: the randomisation procedure (21%), deviations 
from the intended intervention (28%), missing outcome data (28%) and selection of 
reported results (24%). 
Certainty of evidence for all comparisons was low to very low, except for autologous 
blood+eccentric exercise therapy versus placebo injection+eccentric exercise 
therapy, for which there was moderate certainty of evidence (online supplementary 
web appendix 7). The main reasons to rate down the certainty of evidence were study 
91
5
limitations (n=180, 100%) and imprecision (n=158, 88%). We did not rate down for 
inconsistency, indirectness, or publication bias. Only two treatment comparisons were 
studied in multiple (ie, 2) trials (ie, platelet-rich plasma injection+eccentric exercise 
therapy vs placebo injection+eccentric exercise therapy, and laser+eccentric exercise 
therapy vs placebo laser+eccentric exercise therapy). Where this was the case, 
estimates and credible intervals had substantial overlap. Populations, treatments, 
and outcome measures followed those used in clinical practice; hence, there was no 
indication of indirectness in the evidence. We did not assess publication bias because 
there were fewer than 10 trials available for each of the comparisons. 
Network meta-analyses
Figure 2A, B shows direct treatment class comparisons in the field of midportion 
Achilles tendinopathy for VISA-A score. Model fit statistics are reported in online 
supplementary web appendix 8. Ten classes were included in the network analyses. 
None of the networks included evidence from both direct and indirect comparisons, 
so the consistency assumption for NMA could not be checked. Figure 3 shows the 
comparative treatment class effects on the VISA-A score at 3 months (figure 3A) and 
12 months (figure 3B). Figures 4 and 5 show the treatment class rankings for 3 and 
12 months. No class analyses could be performed for the VISA-A score at 6 months 
and return to sports activities at 6 months (only time point in NMA) due to insufficient 
evidence (online supplementary web appendix 8). Treatment effect NMAs for VISA-A 
and return to sports activities are presented in online supplementary web appendix 9. 
No NMA could be performed for insertional Achilles tendinopathy. Studies that could 
not be included in the NMA are presented in online supplementary web appendix 10.
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Figure 2. Network plots for treatment classes on the VISA- A score at 3 and 12 months in 
patients with midportion Achilles tendinopathy. The size of the dots is proportional to the 
number of participants who received the treatment, respectively. Blue numbers indicate the 
number of trials the classes were compared in. Note that intraclass comparisons are not 
included in the plot (eg, eccentric exercises vs heavy slow resistance exercises); all treatment 
comparisons can be found in online supplementary appendix 9. (A) VISA- A score at 3 months. 






































































































































































































































































































































































































































































































































































































































-5 (-19 to 9) Exercise  
therapy
2 (-10 to 13) 7 (-4 to 17) Exercise + injection 
therapy
3 (-16 to 22) 8 (-6 to 21) 1 (-16 to 18) Exercise + night splint 
therapy
Figure 4. Treatment class rankings from the network meta- analysis for the VISA- A score at 
3 months in patients with midportion Achilles tendinopathy. The asterix indicates that the 
95% credible interval was rank 10 to 10 for wait- and- see therapy. MPS, mucopolysaccharides 
supplement; VISA- A, Victorian Institute of Sport Assessment- Achilles.
Figure 5. Treatment class rankings from the network meta- analysis for the VISA- A score at 12 




Comparative treatment class effectiveness on the primary outcome 
(VISA-A score)
VISA-A score at 3 months 
Seventeen treatments, studied in 13 randomised controlled trials (RCTs), were assigned 
to 10 classes. Any treatment seemed superior to wait-and-see: exercise+placebo 
injection therapy (mean difference 19 points, 95% CrI −3 to 34 points), injection 
therapy (23 points, 8 to 38 points), exercise therapy (20 points, 11 to 30 points), 
shockwave therapy (15 points, 6 to 24 points), exercise+injection therapy (22 points, 7 
to 36 points), exercise+shockwave therapy (34 points, 21 to 47 points), exercise+night 
splint therapy (21 points, 4 to 39 points), acupuncture therapy (35 points, 25 to 45 
points) and mucopolysaccharides supplement+exercise therapy (28 points, 14 to 41 
points) (figure 3A). 
Acupuncture therapy seemed superior to placebo injection therapy (16 points, 4 to 
30 points), injection therapy (13 points, 0 to 25 points), exercise therapy (15 points, 
11 to 19 points), shockwave therapy (20 points, 9 to 31 points), exercise+injection 
therapy (13 points, 2 to 25 points), exercise+night splint therapy (14 points, −1 to 30 
points) and mucopolysaccharides supplement+exercise therapy (7 points, −3 to 19 
points), but not to exercise+shockwave therapy (1 point, −9 to 11 points).
Exercise+shockwave therapy seemed superior to placebo injection therapy (15 
points, 1 to 31 points), injection therapy (11 points, −4 to 26 points), exercise therapy 
(14 points, 5 to 23 points), shockwave therapy alone (19 points, 5 to 32 points), 
exercise+injection therapy (12 points, −2 to 27 points) and exercise+night splint 
therapy (13 points, −4 to 30 points), but not to acupuncture therapy (−1 point, −11 
to 9 points) and mucopolysaccharides supplement+exercise therapy (6 points, −7 to 
20 points).
VISA-A score at 12 months 
At 12 months, six treatments, studied in four RCTs, were assigned to four treatment 
classes and compared in a network model. Exercise therapy (−5 points, −19 to 9 
points), exercise+injection therapy (2 points, −10 to 13 points) and exercise+night 
splint therapy (3 points, −16 to 22 points) were all comparable with injection therapy 
(figure 3B).
Treatment class rankings
According to the NMA rankings, acupuncture therapy seemed the best treatment 
at 3 months (mean ranking 1.56, median ranking 1, median’s 95% CrI 1 to 3), and 
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exercise+shockwave therapy seemed second best (mean ranking 1.98, median 
ranking 2, median’s 95% CrI 1 to 5). At 12 months, injection therapy (mean ranking 
2.47, median ranking 2, median’s 95% CrI 1 to 4), exercise therapy (mean ranking 3.51, 
median ranking 4, median’s 95% CrI 2 to 4), exercise+injection therapy (mean ranking 
2.03, median ranking 2, median’s 95% CrI 1 to 4) and exercise+night splint therapy 
(mean ranking 1.99, median ranking 2, median’s 95% CrI 1 to 4) had similar rankings 
(figures 4 and 5).
Comparative treatment class effectiveness on the secondary outcome 
(return to sports activities)
No class analyses could be performed for return to sports activities at 6 months 
(only time point for NMA) due to insufficient evidence. The results of the treatment-
level analyses for return to sports activities at 6 months are presented in online 
supplementary web appendix 9. 
Discussion
In this living systematic review and NMA, none of the trials were at low risk of bias, 
and all evaluated treatments had large uncertainty in the estimates. From a myriad 
of treatments for midportion Achilles tendinopathy, active treatment classes seems 
to have clinically meaningful benefits (mean difference exceeded VISA-A MID of 
14 points) at 3 months compared to wait-and-see.24 For two classes (acupuncture 
therapy, and shockwave therapy combined with exercise therapy), the credible 
intervals exceeded the MID of 14 points. However, these results were based on two 
small trials (64 and 68 included patients, respectively) at high risk of bias. There were 
no estimates for effectiveness of wait-and-see at 12 months. The effectiveness of 
most active treatments in the long term is uncertain. At 12 months, there was no 
difference between exercise therapy, injection therapies and combined therapies. 
Clinical implications
Based on the findings in this study, we advise against recommending wait-and-see 
therapy as a treatment strategy. Active treatments had overlapping comparative 
effects, leaving uncertainty about which treatment is best for Achilles tendinopathy. 
Shared decision-making plays an important role in managing Achilles tendinopathy. 
Safety profile, treatment availability and costs should be considered in this clinical 
decision-making process. Calf-muscle exercise therapy is easy to prescribe because it 




The preinjury activity level could play an important role in the response to treatments 
such as exercise therapy as this will possibly influence the load that can be applied 
to the tendon. There is currently no tool available to distinguish sedentary from 
athletic patients, and people define this differently. When a patient is considered to 
be sedentary, the VISA-A score could be less sensitive to changes as 40% of the score 
can be obtained from sporting activities.23  Therefore, a novel modified version of 
the existing VISA-A questionnaire is currently being developed to evaluate treatment 
response in sedentary individuals.63 In two trials, lower baseline VISA-A score was 
associated with a greater increase in VISA-A score.38 49 This is most likely explained 
by regression to the mean (outliers will tend to move towards the mean score). 
Furthermore, physical activity level was not a prognostic factor for change in VISA-A 
score in the trials that attempted to measure physical activity.34 More research is 
needed to determine whether athletic and sedentary patients should be considered 
separate patient groups. 
Strengths and weaknesses in relation to other studies
The uncertainty around the effectiveness for specific treatments has previously 
been described in Achilles tendinopathy. Most recent meta-analyses on treatment 
effectiveness for Achilles tendinopathy did not find superiority of a single treatment.8 
10 64-66 All other systematic reviews included randomised clinical trials or quasi-
randomised controlled clinical trials and made strong to weak recommendations in 
favour of exercise therapy 8, platelet-rich plasma 66 or against platelet-rich plasma 
10 or splinting 8 single therapies. Our NMA results conflict with a recent systematic 
review with head-to-head meta-analysis where prolotherapy and sclerotherapy 
were superior to other treatments.13 Differences in study selection criteria (case-
series were also included vs only randomised clinical trials in our NMA) and outcome 
measure selection (eg, general Visual Analogue Scale vs a validated patient-reported 
outcome measure in our NMA) may explain the discrepancy. 
Unanswered questions and future research
As uncertainty around treatment effectiveness remains, future trials should be 
adequately powered and designed. Universally agreed diagnostic criteria for 
both insertional and midportion Achilles tendinopathy are needed to prevent 
heterogeneity in included participants. More trials investigating treatment effects for 
insertional Achilles tendinopathy are warranted. New trials should include exercise 
therapy as a stand-alone comparator with long-term (≥12 months) follow-up. This 
would facilitate assessment of the comparative effectiveness of new treatments in the 
network. Based on our findings it is not ethical to perform new studies using wait-and-
see as a treatment arm. The role of patient education has never been explored, but 
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should be further assessed. Trialists must include measures from the core outcome 
set for tendinopathy (patient overall rating, participation, pain on activity/loading, 
disability, function, physical function capacity, quality of life, psychology and pain over 
a specified timeframe).22 We identified eight ongoing trials on the effectiveness of 
multiple treatments for Achilles tendinopathy. We aim to perform horizon scanning 
annually to screen for recently published trials. In case of relevant trials, we will 
update the analyses and publish the results when there are important changes that 
affect clinical care. We plan to update this ‘living’ systematic review and NMA at least 
every 5 years as part of the Dutch national guideline revision process.
Strengths and limitations
We compared treatments in an NMA despite some of these treatments having never 
been compared head-to-head in trials. Our living NMA will be updated at least every 
5 years, which allows for a contemporary evidence synthesis for clinical practice.67 
68 The protocol was registered prospectively and patients were involved in selecting 
outcomes most relevant to them in the design phase. 
The small sample sizes and bias in the included trials limit our conclusions.69 Many 
of the investigated treatments were not connected to the network, which hampered 
assessing the comparative effectiveness of all available treatments. Sources of 
heterogeneity could not be investigated as there were less than the required 10 
trials per comparison. None of the comparisons in the networks had both direct and 
indirect evidence and so we could not check the consistency.17
Treatment outcomes may be different on the basis of some patient characteristics 
and previous Achilles tendinopathy treatment. For example, a sedentary population 
may respond to exercise treatment differently compared with an athletic population. 
Other effect modifiers may be unilateral/bilateral symptoms, duration of symptoms 
and type/number of previous treatments. However, to the best of our knowledge, 
there is presently no evidence supporting any of these factors as treatment effect 
modifiers. The limited amount of study-level data precluded investigating effect 
modification. This may be possible in the future using pooled individual patient data. 
We excluded many trials because they did not use commonly accepted and validated 
outcomes in the field of Achilles tendinopathy.70 It is unclear whether our NMA results 
apply to all patients with Achilles tendinopathy because we only included one trial with 
patients with insertional Achilles tendinopathy. We planned a time course analysis for 
the VISA-A score, as outcomes within the first year are of equal importance. Due to 
a lack of data, we were not able to perform this analysis and, in accordance with our 
protocol, we modelled outcomes for 3 months, 6 months and 12 months instead. 
We planned threshold analysis as a quantitative means to assess the robustness 
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of NMA recommendations to potential limitations in the evidence. We were unable 
to use this approach because of substantial overlap in credible intervals from the 
NMA. Due to overlap in the intervals, no recommendations could be made, which is 
a fundamental prerequisite to performing a valid threshold analysis. To comply with 
our protocol, we report threshold results in online supplementary web appendix 11, 
but chose to use GRADE to interpret the evidence. We were not able to evaluate small 
study bias due to too low number of trials. We found three completed trials in trial 
registers; two are under review, and the publication status of one trial is unknown. 
Therefore, it seems unlikely that, in an era of prospective trial registrations, significant 
publication bias is present in the field of Achilles tendinopathy.
Conclusion
Our living NMA of 29 RCTs on Achilles tendinopathy included 42 different treatments. 
No trials were at low risk of bias, most had only short follow-up, and there was large 
uncertainty in the comparative estimates. For midportion Achilles tendinopathy, 
active treatments seem superior to wait-and-see at 3-month follow-up. There was no 
evidence of a clinically relevant difference in effectiveness between different active 
treatments at 3-month and 12-month follow-up. Calf-muscle exercise therapy is 
easy to prescribe in practice, is widely available, and is regarded as safe and cheap. 
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Isometric exercises do not 
provide immediate pain relief 
in Achilles tendinopathy: 
a quasi-randomised clinical 
trial
Arco C van der Vlist, Peter LJ van Veldhoven, Robert F van Oosterom, 
Jan AN Verhaar, Robert-Jan de Vos




Background: Isometric exercises may provide an immediate analgesic effect in 
patients with lower-limb tendinopathy and have been proposed as initial treatment 
and for immediate pain relief. Current evidence is conflicting, and previous studies 
were small. 
Objective: To study whether isometric exercises result in an immediate analgesic 
effect in patients with chronic midportion Achilles tendinopathy. 
Methods: Patients with clinically diagnosed chronic midportion Achilles tendinopathy 
were quasi-randomised to one of four arms: isometric calf-muscle exercises (tiptoes), 
isometric calf-muscle exercises (dorsiflexed ankle position), isotonic calf muscle 
exercises, or rest. The primary outcome was pain measured on a visual analogue 
scale (VAS) score (0-100) during a functional task (10 unilateral hops) both before and 
after the intervention. Between-group differences were analysed using a generalized 
estimation equations model. 
Results: We included 91 patients. There was no significant reduction in pain on the 10 
hop test after performing any of the four interventions: isometric (tiptoes) group 0.2, 
95%CI −11.2 to 11.5; isometric (dorsiflexed) group −1.9, 95%CI −13.6 to 9.7; isotonic 
group 1.4, 95%CI −8.3 to 11.1; and rest group 7.2, 95%CI −2.4 to 16.7. There were also 
no between-group differences after the interventions. 
Conclusion: The isometric exercises investigated in this study did not result in 
immediate analgesic benefit in patients with chronic midportion Achilles tendinopathy. 
We do not recommend isometric exercises if the aim is providing immediate pain 
relief. Future research should focus on the use of isometric or isotonic exercise 





Chronic tendon overuse injuries (tendinopathy) are common and account for 30-50% 
of all sports-related injuries.1 Achilles tendinopathy (AT) is common in runners with up 
to 52% of athletes being affected during their lifetime.2 3 AT is a clinical diagnosis based 
on a combination of local Achilles tendon pain, swelling of the Achilles tendon, and an 
impaired load-bearing capacity.4 5 Treatment outcomes are often disappointing, with 
persisting symptoms in 35%-60% of the patients at 5-year follow-up.6 7 
The underlying histopathology of tendinopathy is an increased tenocyte response 
and local disorganization of the tendon structure.8 9 The severity of local tendon 
tissue disorganization is, however, not directly related to the degree of pain.10 11 As 
a result, peripheral pain is not considered to be the only driver of pain sensation in 
tendinopathy. Recent evidence found that altered central pain processing might be 
an important factor in persisting Achilles tendon pain, with pathophysiological pain 
(central sensitization) as a result.12-14 These alterations in central pain processing may 
explain why AT can be resistant to tissue-based treatment options.15 
Isometric exercises of several muscle groups (eg, quadriceps muscles) have 
been found to influence central pain processing.16 17 These changes resulted in a 
substantial immediate analgesic effect in patients with patellar tendinopathy.18 19 As a 
consequence, it has been suggested that isometric exercises can be used to provide 
immediate pain relief for athletes as ‘in-season management’.20 To date only one 
research group has investigated the immediate analgesic effect of isometric exercises 
in AT. No reduction in pain was found in this study after the performance of isometric 
exercises of the calf muscles.21 The power of all previous studies was limited, and a 
clinically relevant immediate effect of exercises cannot be excluded, as no control 
groups were included in which no exercises were performed.18 19 21 As the current 
treatment advices of tendinopathy are being influenced by these heterogeneous 
findings,22 it is important to clarify the role of isometric exercises in AT. 
Our primary aim was to determine the immediate effect of isometric exercises on 
pain during a functional task in patients with chronic midportion AT. The secondary 
aim was to compare these results with the effect after the performance of isotonic 
exercises and rest. 
Methods 
Study design
This quasi-randomised clinical trial with four intervention arms was conducted as a 
part of a randomised clinical trial (RCT). The aim of this larger RCT was to evaluate the 
effect of a high-volume injection in patients with chronic midportion AT (ClinicalTrials.
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gov Identifier: NCT02996409). The current study was performed before patients 
received any type of intervention, and the outcome of the current study did not affect 
participation in the larger RCT. All patients provided written informed consent prior to 
participation. The protocol of the study was approved by the regional Medical Ethical 
Committee (registration number 14-100). Study findings are reported following 
the CONSORT guideline, the Pain specific CONSORT supplement checklist, and the 
TIDieR guideline for reporting interventions. Originally, the aim was to compare three 
intervention arms: isometric exercises (tiptoes), isotonic exercises, and rest. During 
the course of the study, there was enhanced insight in this research field that the joint 
position could influence the analgesic effect as previous research demonstrated that 
tendon loading varies at different joint positions.23 Therefore, we decided to add an 
intervention arm in which isometric exercises were performed with the ankle dorsiflexed. 
Setting and subjects
This clinical trial was performed at the Sports Medicine department in a large district 
general hospital (Haaglanden Medical Centre, Leidschendam, the Netherlands) and 
a university medical centre (Erasmus MC University Medical Centre, Rotterdam, the 
Netherlands). All 80 patients who were included in the RCT participated also in the 
current study. Additionally, patients with AT who presented after inclusion of the larger 
RCT was completed were allowed to still participate when visiting one of these research 
centres. Inclusion was carried out by two sports medicine physicians. Inclusion criteria 
were as follows: (a) the presence of chronic midportion AT for at least 2 months, (b) 
no subjective symptomatic improvement after exercise therapy of at least 6 weeks, (c) 
aged between 18-70 years, and (d) the presence of Doppler flow on power Doppler 
ultrasonography. The diagnosis was established based on clinical examination (local 
tendon pain and swelling of the Achilles tendon 2-7 cm proximal to its calcaneal 
insertion, and impaired load-bearing capacity) by the sports medicine physician. The 
main exclusion criteria were as follows: (a) a clinical suspicion of other musculoskeletal 
disorders (insertional AT, inflammatory internal disorders, quinolone-, corticosteroid- 
or statin-induced tendinopathy), (b) a previous Achilles tendon rupture or surgery, (c) 
the inability to perform an exercise program, and (d) a medical condition that could 
affect the safety of the injection in the larger RCT (eg, peripheral vascular disease or 
use of anticoagulant medication). Detailed information regarding all eligibility criteria is 
provided in the trial registration. In case of bilateral symptoms, the patient selected the 
most symptomatic tendon for inclusion in this study.
Quasi-randomization
Patients were originally allocated to one of the three intervention arms based on 
the inclusion number in the larger RCT. Using this method of quasi-randomization, 
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all patients were equally distributed between the groups. The last 11 participants in 
the larger RCT and seven extra patients who visited the outpatient department for 
clinical care (18 in total) were allocated to the additional intervention arm performing 
isometric exercises with a dorsiflexed position of the ankle.
Interventions
The intervention arms consisted of a specific loading protocol or a period of rest. 
Patients were told that the loading exercises were performed to determine the 
maximum amount of weight that could be lifted to personalise the exercise program 
for the following weeks. Patients in the rest group were asked to sit on a chair while 
they received verbal instructions regarding the exercise program for the following 
weeks. The hypothesis of the current study was therefore unknown to all participants. 
Instructions were provided by a single non-blinded, trained PhD-candidate with 
2 years of practical medical training who included patients at both research centres. 
The interventions were based on previous work in this research field.18 21 Of a total 
of four intervention arms, three groups performed plantar flexor contractions both 
in seated and standing position and the control group rested. The different loading 
protocols are presented in Table 1. The duration of all programs was identical (13 
minutes). Prior to the programs, patients completed a warming-up consisting of 
walking up and down four flights of stairs followed by 1 minute of non-loaded mobility 
exercises of the ankle. Patients were subsequently instructed that exercises should 
be performed at maximal intensity and may be painful. Patients were instructed to 
ignore pain unless it was unbearable. Patients started with an additional weight of 30 
kg for the first set in seated position of the loading protocols. Standardised feedback 
was provided during the loading protocols (“come-on, half-way there”). 
112
Chapter 6
Table 1. Interventions used in the study. For the plantar flexor contraction groups, five sets of 
exercises were performed, of which two sessions were performed with the knee bent followed 
by three sessions with the knee extended. Exercises were performed barefoot under supervision 
of the researcher. All patients rested for two minutes between sets to allow sufficient recovery. 
A stopwatch was used to control for the prescribed contraction and rest times. Joint positions 
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Rest - - 13
Abbreviations: rep, repetitions; s, seconds
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The rate of perceived exertion (RPE) was recorded between sets. A score of 0 indicates 
rest and a score of 10 maximal effort. If exercises were relatively easy to perform 
(RPE < 7), additional weight was applied using weighted vests up to a maximum of 60 
kg and adjustable per 1.5 kg (in seated position resting on the upper leg). To evaluate 
intensity of the loading protocols, an overall RPE score for the loading protocol was 
obtained after the performance of all sets of exercises. The weight was lowered in 
case of unbearable pain or when patients could not complete the contraction times. 
Test methods
Demographic details
We recorded the following relevant baseline characteristics: age, sex, body mass index 
(BMI), activity (active or sedentary), sports participation (hours/wk), affected side, duration 
of symptoms, and Victorian Institute of Sport Assessment-Achilles (VISA-A) score.24 
Outcome measures
The primary outcome measure we used was the patient-reported pain after the 
performance of 10 unilateral hops.25 26 We used this outcome measure to test the 
immediate effect primarily of isometric exercises, but also for isotonic exercises and 
rest as secondary outcome. According to a recent consensus meeting with patients 
and healthcare professionals, pain on loading was found to be one of the core domains 
for tendinopathy.27 Patient-reported pain was measured using a visual analogue scale 
(VAS) ruler with slider, in which 0 represents no pain and 100 represents the worst 
pain imaginable. This outcome measure (10 hop VAS-score) was assessed at the start 
of and immediately after the intervention. To evaluate success of the procedure, we 
evaluated the mean added weight (in kg) during the loading protocol both in the 
seated and standing position. Additionally, we started to obtain the RPE scores (0-10) 
after the first 20 inclusions to determine whether exercises were performed with 
sufficient effort due to empirical knowledge. 
Statistical analyses 
Our sample size calculation showed that 16 patients in each group were required to 
detect a minimal clinically important difference of 20 points on the VAS-score (power 
0.80, 2-sided significance level 0.05, SD 20).21 28 29 Data were analysed using SPSS 
25.0.0.1 (SPSS Inc.) according to a statistical analysis plan uploaded on clinicaltrials.
gov before evaluating the last patient in the RCT. Within-group differences of the 
10 hop VAS-scores were analysed using a Generalized Estimation Equations (GEE) 
model. To test whether changes in VAS-score before and after the program were 
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different between groups, we added the interaction term of intervention arm*pre/
post testing. Adjustments were made for the following pre-defined baseline variables: 
age, sex, BMI, baseline VISA-A score, and duration of symptoms. Outcomes of the 
GEE-model are presented as estimated marginal means with their 95% confidence 
interval, unless otherwise stated. Between-group differences in the RPE score and the 
added weight during the loading protocol were analysed using a one-way ANOVA test. 
Differences of P < .05 were considered to be statistically significant. Missing data were 
not imputed, but we planned to perform sensitivity analyses if missing data would 
exceed 5% for a certain time point.30




From December 2016 to August 2019, 196 patients were screened for eligibility and 91 
patients were included and allocated to one of the four intervention arms (Figure 1). 
Only one patient in the isotonic group could not perform the complete loading 
protocol due to time restraints (assessment primary outcome before intervention 
available, but not post-intervention). There were no visual or statistical differences 
in the majority of the baseline characteristics between the four intervention arms 
(Table 2), except for the BMI which was higher in the rest group compared to the 
isometric (tiptoes) group and the VISA-A score that was lower in the isometric 
(dorsiflexed) group compared to both the isotonic group and the rest group. Both 
these characteristics were already included in the GEE-model. 
Primary outcome measure – patient-reported pain
The within-group differences in estimated mean 10 hop VAS-score were not 
statistically significant in all the intervention groups as presented in Table 3. Ten hop 
VAS-scores are presented as raw individual patient data and mean scores in Figure 2. 
The interaction term intervention arm*pre/post -testing was not statistically significant 
(P = .26), meaning that the change in 10 hop VAS-score did not differ between the four 
groups. Between-group differences were thus all not statistically significant after the 
interventions (Table 3). The unadjusted analyses are reported in Web Appendix 1.
Success of procedures
The mean (SD) RPE (0-10) during the loading protocol was 7.0 (1.7) in the isometric 
(tiptoes) group (n = 17), 7.7 (1.2) in the isometric (dorsiflexed) group (n = 18), and 7.8 
(1.5) in the isotonic group (n = 17). The mean (SD) added weight during the loading 
protocol in seated position was 28 kg (7) in the isometric (tiptoes) group, 31 kg (4) in 
the isometric (dorsiflexed) group, and 30 kg (4) in the isotonic group. In the standing 
position, the mean (SD) added weight was 25 kg (12) in the isometric (tiptoes) group, 
16 kg (16) in the isometric (dorsiflexed) group, and 22 kg (12) in the isotonic group. 
Between-group differences were not statistically significant for the mean RPE (P = .22), 
the mean added weight in seated position (P = .28), and the mean added weight in 
standing position (P = .10). 
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Age, y 47.3 (10.9) 47.6 (9.3) 48.7 (7.4) 49.7 (7.4) 0.775
Sex, male, n (%) 9 (38) 9 (50) 13 (54) 14 (56) 0.569
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week), median (IQR)

















62.0 (120) 104.0 (98) 88.0 (61) 59.0 (46) 0.223
VISA-A score2 42.8 (15.1) 32.7 (13.5) 46.0 (15.5) 45.2 (14.7) 0.0235
Data are presented as mean ± SD unless otherwise specified.
Abbreviations: BMI, body mass index; IQR, interquartile range; n, number of participants; SD, standard 
deviation; VISA-A, Victorian Institute of Sports Assessment-Achilles; wk, weeks; y, years.
1 To determine whether participants were active or sedentary we used the ankle-activity score. If the score was 
≥4 points the participant was considered to be active (starting from heavy physical work). If the score was ≤3 
points the participant was considered to be sedentary (cycling, equestrian or less activity). Sports participation 
is only presented for the active group.31
2 The VISA-A questionnaire consists of eight questions and covers three domains of Achilles tendon symptoms: 
pain, activity, and function. Scores vary from 0 to 100 where 100 indicate an asymptomatic person and 0 is 
defined as maximum pain, no activity, and no function.
3 P-values for between-group differences in baseline characteristics were calculated using the one-way ANOVA 
for normally distributed continuous outcomes, the Kruskal Wallis test for non-normally distributed outcomes, 
and the chi-square test for categorical outcomes. 
4 Post hoc testing with Bonferroni correction showed there was a significant difference in BMI between 
the isometric (tiptoes) group and the rest group (p=0.05). There were no other significant between-group 
differences. 
5 Post hoc testing with Bonferroni correction showed there were significant differences in VISA-A score 
between the isometric (dorsiflexed) group and both the isotonic group and the rest group (p=0.031 and 
p=0.047). There were no other significant between-group differences. 
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Figure 2: Individual patient data and means per intervention arm (A-D) for the patient-reported 
pain (visual analogue scale (VAS) score) immediately after performing 10 unilateral hops. VAS-
scores were assessed before (pre) and immediately after the intervention (post). The grey lines 
represent the individual VAS-scores, the black line the raw mean VAS-scores of the intervention 
arm. No statistically significant differences between the four intervention arms were found. A 
clinical relevant immediate analgesic effect of 20 points was detected in six patients (25%) in 
the isometric (tiptoes) group, 3 patients (17%) in the isometric (dorsiflexed) group, four patients 
(17%) in the isotonic group, and 1 patient (4%) rest group. 
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Table 3. Outcomes of the Generalized Estimation Equations (GEE) model used to evaluate 
whether any of the loading protocols/rest provided an immediate analgesic effect. Adjustments 
were made for the following pre-defined baseline variables: age, sex, BMI, baseline VISA-A score 
and duration of symptoms. Outcomes of the GEE-model are presented as estimated marginal 
means with their 95% confidence interval. A higher 10 hop VAS-score indicates more pain. 
Positive values for the between-group differences correspond to more improvement in 10 hop 
VAS-score compared to the other intervention group. Negative values correspond with less 
improvement in 10 hop VAS-score compared to the other intervention group.
Estimated mean 10 hop VAS-scores (0-100) before and after the performance of one of 
the interventions




39.7 (31.8 to 47.6) 39.9 (29.9 to 49.8) 0.2 (-11.2 to 11.5)
Isometric 
(dorsiflexed)
41.7 (29.0 to 54.4) 39.8 (28.2 to 51.3) -1.9 (-13.6 to 9.7)
Isotonic 44.8 (37.7 to 51.8) 46.2 (37.9 to 54.5) 1.4 (-8.3 to 11.1)
Rest 44.7 (35.7 to 53.7) 51.9 (43.1 to 60.6) 7.2 (-2.4 to 16.7)









0.1 (-24.9 to 25.1) -6.3 (-27.4 to 14.7) -12.0 (-33.2 to 9.2)
Isometric 
(dorsiflexed)
-6.4 (-29.9 to 17.0) -12.1 (-34.9 to 10.7)
Isotonic -5.7 (-24.8 to 13.5)
Rest
Abbreviations: VAS, visual analogue scale.
Discussion 
Summary of main findings 
Our trial compared the effects of two different isometric exercises, isotonic exercises, 
or resting on pain during a functional test in chronic midportion Achilles tendinopathy. 
Neither isometric nor isotonic exercises provided an immediate analgesic effect.
Clinical implications
Our findings are important and clinically relevant, since the performance of isometric 
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exercises has become increasingly popular as initial treatment and for immediate 
pain relief in several lower-limb tendinopathies. The popularity is based on a study 
that found a large and meaningful decrease in pain score of 6.8 (scale 0-10) following 
isometric exercises in patients with patellar tendinopathy, compared to a decrease of 
2.6 points following isotonic exercises.18 Despite the fact that this was a single study 
with a very small sample size (n=6), isometric exercises were implemented rapidly.32 
Results were quickly extrapolated to other lower-limb tendinopathies such as AT.32 
To date, one other research group investigated the analgesic effect of isometric 
exercises in a relatively small group of patients (n  =  16) with chronic midportion 
AT. Heterogeneous individual responses were found, with no overall meaningful 
change in pain scores during a functional task after performing isometric exercises.21 
A difference between that particular study and ours is that in the previous study 
patients performed exercises using a Wii platform. We performed the exercises in 
the way they are performed in the clinical setting during rehabilitation with the use 
of additional weight. Comparable results with no meaningful change were also found 
in patients with lateral elbow tendinopathy, plantar fasciopathy, and a recent second 
study in patellar tendinopathy.19 29 33 We also demonstrated no meaningful change in 
pain score after the performance of isometric exercises with either a dorsiflexed or a 
plantar flexed position of the ankle. 
In previous research, isotonic exercises provided immediate pain relief with small 
magnitude in patellar tendinopathy.18 This is the first study to investigate the possible 
analgesic effect of isotonic exercises in AT. We also found no meaningful change in 
pain score after isotonic exercises. Our study was the first to include a rest group in 
which no exercises were performed. Results of the intervention arms performing a 
loading protocol did not differ from the rest group, indicating that both isometric and 
isotonic calf-muscle exercises have no immediate analgesic effect. 
Research implications
The previous study in patients with chronic midportion AT demonstrated that the 
severity of symptoms could play a role in the analgesic effect of isometric exercises. 
Individuals with higher pain scores worsened in that study, compared to individuals 
with lower pain scores who improved after isometric exercises.21 We did not replicate 
this finding with our study, as the individual responses to the intervention were very 
heterogeneous (Figure 2). More research would be needed to determine whether 
subgroups are present and if so, whether different treatment regimens should be 
provided. This would involve very large study numbers. We did not investigate the role 
of isometric or isotonic exercises as an actual treatment for AT, and more research 
regarding the efficacy of the different exercise programs on the intermediate and 
long-term effects is necessary.34 Our study shows that both types of exercises also 
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do not aggravate immediate pain. Both exercises are well-tolerated and could 
represent a starting point for therapy, self-efficacy, and self-management. We also 
did not investigate the analgesic effect of isometric exercises in patients with a short 
symptom duration (reactive stage). It could be hypothesised that possible cortical 
reorganization depends on the chronicity of symptoms, making patients with chronic 
symptoms less sensitive to an analgesic effect of isometric exercises. 
Strengths and limitations
This is the largest study to date investigating the immediate analgesic effect of both 
isometric (two groups with different ankle positions) and isotonic exercises in patients 
suffering from tendinopathy. This is also the first study to include a control group who 
rested to rule out an analgesic effect from activation of the musculotendinous unit.
 Despite our robust research design, there are some methodological limitations. First, 
we estimated our sample size on a SD of 20 points. However, it transpired that the SD 
of the changes in the VAS scores was approximately 26 points and thus 28 patients 
per group would have been required to detect a meaningful change. Additionally, 
the secondary outcomes could also be slightly underpowered as multiple testing 
was performed. If we would adjust the alpha level using the Bonferroni method for a 
total of 6 comparisons, 41 patients per group would have been required. However, 
if we overlook the mean between-group differences and the very few responders, 
it is unlikely that this study does involve a type II error. Furthermore, the above-
mentioned potential limitations do not influence our primary aim to determine 
whether isometric exercises provide an immediate analgesic effect. Second, the 
method of quasi-randomization was used to allocate patients to the intervention 
arms. Although this method is not preferable, it was most appropriate as patients 
were already being randomised to evaluate the effect of an injection treatment. We 
also adjusted for relevant pre-defined baseline variables in the GEE-model, making it 
unlikely that differences in baseline characteristics will have influenced results. Third, it 
was not feasible to blind the outcome assessor (patients) for the type of intervention. 
However, we did not mention the hypothesis of the study and in doing so avoided 
influencing patient beliefs regarding the immediate effect of exercise therapy. Fourth, 
patient beliefs regarding exercise therapy could already be influenced since absence 
of symptomatic improvement after exercise therapy at short term (at least 6 weeks) 
was an inclusion criterion. It is, therefore, questionable whether we could extrapolate 
these results to the broader population of patients with midportion Achilles 
tendinopathy. Fifth, we did not obtain the RPE scores from the first 20 inclusions. 
The RPE was still obtained in the majority of the patients (17/24) in both the isometric 
(tiptoes) group and the isotonic group and in all 18 patients within the isometric 
(dorsiflexed) group. Sixth, some patients (n = 9) had a 10 hop VAS-score of zero at the 
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start of the exercise therapy and could thus not show an immediate analgesic effect. 
Additional sensitivity analyses excluding those patients did not affect outcomes of this 
study. Future studies are advised to exclude these patients in their trial. 
Perspective 
Isometric and isotonic exercises do not result in immediate pain relief in patients 
with chronic midportion AT. After one small study investigating patients with patellar 
tendinopathy demonstrated that isometric exercises resulted in a large immediate 
pain relief, these exercises gained a lot of attention and were implemented rapidly. A 
recent smaller study in patients with AT was not able to replicate these findings. As a 
result, there was conflicting evidence for the analgesic effect of isometric exercises. 
Based on the findings in this study, we do not recommend the use of isometric 
exercises for immediate pain relief in patients with chronic midportion AT. Future 
research should focus on the intermediate and long-term efficacy of isometric and 
isotonic exercises as a treatment for AT and the analgesic effect of isometric exercises 
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Objective: To study whether a high-volume injection without corticosteroids improves 
clinical outcome in addition to usual care for adults with chronic midportion Achilles 
tendinopathy.
Design: Patient and assessor-blinded, placebo-controlled randomised clinical trial.
Setting: Sports medicine department of a large district general hospital, the Netherlands.
Participants: 80 adults aged 18-70 years with clinically diagnosed chronic midportion 
Achilles tendinopathy and neovascularisation on ultrasonography were eligible to 
participate. 39 were randomised to a high-volume injection without corticosteroids 
and 41 to placebo. 
Interventions: Participants were instructed to perform an exercise programme for 
24 weeks (usual care) combined with one 50 mL high-volume injection of saline and 
lidocaine (intervention group) or one 2 mL placebo injection of saline and lidocaine 
(placebo group) at baseline. 
Main outcome measures: Primary outcome was pain and function assessed using 
the validated Victorian Institute of Sports Assessment-Achilles (VISA-A) questionnaire 
at 24 weeks (analysed using a generalised estimation equations model). Secondary 
outcomes were patient satisfaction, return to sport, degree of ultrasonographic Doppler 
flow, visual analogue scale on 10-hop test, power and flexibility of the gastrocnemius 
and soleus muscles, pain detect questionnaire for neuropathic pain, and pain coping 
inventory. Participants were evaluated at baseline and at 2, 6, 12, and 24 weeks.
Results: Only one participant (1%) was lost to follow-up. The estimated mean VISA-A 
score improved significantly, from 40.4 (95% confidence interval 32.0 to 48.7) at 
baseline to 59.1 (50.4 to 67.8) at 24 weeks in the high-volume injection group and 
from 36.9 (27.1 to 46.8) to 58.5 (47.9 to 69.1) in the placebo group. The VISA-A score 
over time did not differ between the groups (adjusted between group difference at 
24 weeks 0.5 points, 95% confidence interval −17.8 to 18.8). No significant between 
group differences were found for patient satisfaction (21/37 (57%) v 19/39 (49%) 
patients, P=0.50) and return to desired sport (15/29 (52%) v 19/31 (61%) patients 
active in sports, P=0.65) at 24 weeks. None of the other secondary outcomes differed 
between the two groups.
Conclusions: A high-volume injection without corticosteroids in addition to usual care 
is not effective for symptom reduction in patients with chronic midportion Achilles 
tendinopathy. On the basis of our findings, we cannot recommend the use of a high-
volume injection in this patient group.




Chronic disorders of the Achilles tendon (tendinopathy) are a common overuse 
injury seen in general practice, with an incidence rate of 2-3 per 1,000 registered 
adult patients.1 Most (74%) of these patients have midportion Achilles tendinopathy.2 
Runners are most at risk of developing symptoms, with a lifetime risk of 52%.3 The initial 
treatment of Achilles tendinopathy is exercise combined with load management.4 
Despite initiation of treatments, two thirds of patients continue to have symptoms 
at one year follow-up.5 At 10-years follow-up, about a quarter of patients still have 
symptoms.5 6 About one third of these non-responders eventually require surgery.4 
7 Therefore, effective conservative treatment options are necessary to improve the 
outcome of patients with chronic Achilles tendinopathy who fail to respond to initial 
exercise treatment. 
Formation of blood vessels (neovascularisation) around and within the tendon is one 
of the features of chronic Achilles tendinopathy. Neovascularisation can be identified 
in 50-100% of patients with tendon symptoms using Doppler ultrasonography, 
compared with 0-30% in asymptomatic patients.8-12 The infiltration of nerve structures 
alongside this neovascularisation has been suggested to play a role in the chronicity of 
pain from Achilles tendinopathy.13 14 A large study showed an association between the 
degree of ultrasonographic Doppler flow and patient-reported severity of symptoms.8 
Consequently, treatments have been developed to target neovascularisation. A novel 
technique is high-volume injection, in which a large amount of fluid is injected into 
the area surrounding the tendon with the aim of obliterating peritendinous and 
intratendinous neovascularisation from high mechanical pressure.14 Current debate 
is on the addition of corticosteroids to the injection mixture. Recent evidence shows 
that a high-volume injection with corticosteroids is associated with superior short-
term improvement at 6-12 weeks compared with a high-volume injection without 
corticosteroids, but intermediate term effects are similar.15 Several cohort studies 
and one small randomised controlled trial found that a high-volume injection (both 
with and without corticosteroids) resulted in decreased pain and improved function 
in the short-term (6-12 weeks).14 16-19 As a consequence, this treatment is increasingly 
being used in the clinical setting although its effectiveness has not been tested in 
a large well designed study. In this study, we compared the effect of a high-volume 
injection without corticosteroids with a placebo injection (both combined with an 
exercise programme) on pain and functional outcome at 24 weeks in patients with 




Study design and participants
This study was conducted as a stratified, patient and assessor-blinded, placebo-
controlled, randomised clinical trial with 1:1 allocation ratio at the sports medicine 
department of a large district general hospital (Haaglanden Medical Centre, The Hague, 
Netherlands). The study was announced through letters to healthcare professionals, 
presentations at national conferences, and information on a national sports medicine 
platform. Potentially eligible participants were identified from referrals by healthcare 
providers and self-referrals, thereby comprising a mix of patients with and without 
primary care from healthcare providers. The coordinating researcher (AvdV) provided 
participants with detailed information on the study. Participants were screened for 
eligibility by telephone and online (using a pain map). A sports medicine physician 
(RvO) evaluated potentially eligible participants for inclusion at a booked appointment. 
Participants provided written informed consent before inclusion.
We included patients if they were aged 18-70 years, had a painful swelling of the 
Achilles tendon 2-7 cm proximal to the insertion on the calcaneus, had had 
symptoms for at least two months, had an unsatisfactory outcome after a six week 
exercise programme, and had detectable Doppler flow. When symptoms were 
bilateral, participants selected the most severely affected tendon for treatment. All 
the participants performed a minimum of six weeks of exercise treatment before 
inclusion.
Patients were excluded if they had a history of an Achilles tendon rupture or surgery; 
were unable to perform the exercise programme, were engaged in concomitant 
treatment programmes, had sural nerve disease, had recent drug use (within two 
years) with putative effect on symptoms and tendon healing (quinolone antibiotics, 
corticosteroids), were suspected of having other musculoskeletal disorders clinically 
(insertional Achilles tendinopathy, plantar flexor tenosynovitis, peroneal subluxation, 
inflammatory internal disorders, or quinolone, corticosteroid, or statin induced 
tendinopathy), had a medical condition that would affect the safety of the participant 
when using the injection (eg, peripheral vascular disease, use of anticoagulant drugs, 
allergy for lidocaine), or were pregnant.
Procedures
One researcher (AvdV) prepared five 10-mL syringes (total volume 50 mL) for each 
patient. These syringes contained a mixture of 8 mL 0.9% sodium chloride solution 
(saline) and 2 mL 1% lidocaine (B Braun; Melsungen, Germany). Before and directly 
after injection, we used a Pro Focus Type 2202 (BK Medical; Herlev, Denmark) with a 
5-12 MHz linear probe type 8811 to perform ultrasonography. The area of maximum 
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Doppler flow was detected using power Doppler ultrasonography with predefined 
settings determined before the start of the study (mechanical index 1.28, thermal 
index 1.2, pulse repetition frequency 1.0 kHz and gain 50%).20 We recorded the 
presence of intratendinous and peritendinous Doppler flow immediately after the 
injection. A blinded observer evaluated the presence of Doppler flow on these records 
to verify the success of the procedure after the trial has ended. These results had no 
consequences on the injection procedure - that is no second injection was performed 
if Doppler flow was still present after the high-volume injection. Complications and co-
interventions were registered at each visit. All participants received daily compliance 
logs to complete for evaluation of adherence to the exercise programme. The 
participants were asked to upload these logs digitally every week. Reminders were 
sent to non-responders after five days.
Randomisation and masking
We used stratification for pre-injury activity level, since this could be a confounder 
for the primary outcome of pain and functional activity using the Victorian Institute 
of Sports Assessment-Achilles (VISA-A) questionnaire.21 Stratification was conducted 
using the ankle activity score, which quantifies ankle-related activity based on 
type and level of activities.22 Participants with an ankle activity score of 4 points 
or more were considered to be active those with a score of 3 points or less were 
considered to be sedentary.23 Participants were randomised using a computer-
generated randomisation list (Microsoft Access; Redmond, WA). To ensure a balance 
between the number of participants in each treatment group, we performed block 
randomisation with a variable block size of 4-10). To ensure blinding of the outcome 
assessor (AV), a secretary performed the randomisation who was independent of the 
researchers responsible for enrolment or the assessment of outcome measures. After 
randomisation, an unblinded sports medicine physician (RvO) who was not involved in 
the assessment of outcome measures carried out the allocated injection treatment. 
The participants were blinded to their assigned treatment, as they could not see the 
injection procedure. All the participants completed a short questionnaire immediately 
after the injection to check whether the blinding procedure was successful (which 
type of injection do you think you have received (high-volume injection or placebo)?) 




The participants were placed in the prone position on the examination table with the 
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affected ankle hanging over the edge of the table. To ensure blinding, participants 
were asked not to turn their head during the injection procedure. The sports medicine 
physician inserted a 21-gauge and 40 mm long needle from the medial side of the 
ankle between the anterior aspect of the Achilles tendon and the anteriorly located 
Kager’s fat pad. The needle was attached to a connecting tube of 30 cm with Luer 
taper (Argon MC; Frisco, TX) to attach the syringes on the other side. The first syringe 
with the saline and lidocaine mixture (10 mL) was injected at the area of maximum 
Doppler flow. The following four syringes (10 mL each) were injected 1-2 cm proximal, 
distal, medial, and lateral, with coverage of the whole width of the tendon under 
real-time ultrasonography. The injection technique was identical to that described 
previously.14 Materials were stored in an opaque box to ensure blinding of the 
participants after the injection. The participants remained prone on the examination 
table for 5-7 minutes after the procedure. 
Placebo Injection
The placebo injection was performed using a similar technique, mixture, and duration 
as for the high-volume injection. The only difference was the amount of injected fluid. 
Except for the third syringe, only 0.5 mL of each of the five syringes was injected at the 
different injection locations in the placebo group. The third syringe was attached to 
the connecting tube and the needle was localised at the injection site, but no fluid was 
injected. Therefore, 2 mL of the saline and lidocaine mixture was injected in total. To 
ensure blinding, the participants were unaware of the amount of injected fluid and type 
of procedure used for either treatment group. The participants were advised to refrain 
from strenuous walks and sports activities during the first 24 hours after the injection.
Exercise programme
The blinded outcome assessor (AV) instructed all participants to perform a daily 
calf muscle exercise programme using detailed written information and videos. 
The exercise programme was based on an existing protocol, consisting of three 
consecutive phases: isometric exercises, concentric exercises, and eccentric 
exercises.24 25 The participants were asked to start the next phase if exercises could 
be performed for one week with acceptable symptoms (visual analogue scale score of 
≤3/10 in activities and in daily life). If eccentric exercises could be performed without 
problems for at least one week, the participants continued with the return to sports 
module. This module consisted of four phases: simple plyometric exercises, fast 
plyometric exercises, a gradual increase in running, and interval training (if necessary 
for the type of sports). Web appendix 1 provides detailed information on the exercise 
programme and return to sport module.
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All the participants were advised to refrain from weightbearing sporting activities for 
at least five weeks. The exercises and activities should be performed with only mild 
pain (maximum score of 3 on a scale from 0 to 10, with 0 indicating no pain and 10 
maximum pain) and the participants were advised to decrease the activity level when 
the pain increased to more than 3 points during or after the activity or when morning 
stiffness increased one day after the activity compared with the previous days.24 
The participants were then instructed to decrease their activity until symptoms had 
returned to an acceptable level. They were discouraged from using other treatments 
for their Achilles tendinopathy.
Outcome measures
The primary outcome measure was the Dutch version of the VISA-A questionnaire.26 
This validated and disease-specific questionnaire quantifies pain and activity levels, 
with scores ranging from 0 to 100: 100 indicates no pain with full activity level, with 
the score decreasing with increasing severity of symptoms.27. 
Secondary outcomes were patient satisfaction, return to sport, degree of 
ultrasonographic Doppler flow, visual analogue scale on 10-hop test, power and 
flexibility of the gastrocnemius and soleus muscles, pain detect questionnaire, and pain 
coping inventory. Patient satisfaction was scored as moderate or poor or as excellent 
or good. Return to sport was scored as “no return to the desired sport” or “return to 
the desired sport” (regardless of reaching pre-injury level). All outcome measures were 
assessed at baseline (before intervention) and at 2, 6, 12, and 24 weeks. 
Statistical analysis
Our sample size calculation showed that 40 participants were required in each 
group to detect a difference of 12 points on the VISA-A score (power 0.80, two sided 
significance level of 0.05, SD 18, and accounting for a 10% loss to follow-up).23 28 29 
A researcher (AvdV) performed the statistical analyses under the supervision of a 
biomedical statistician (JW); both were blinded to the allocated treatment. Data 
were analysed on an intention-to-treat basis using SPSS 25.0.0.1 (SPSS, Chicago, IL). 
Normality of the data was checked visually with Q-Q plots and statistically using the 
Shapiro-Wilk test. Between-group differences for the primary outcome were analysed 
using a generalised estimation equations model. To test whether the time course 
of the VISA-A score was different between groups we added the interaction term 
of treatment group x time point. Adjustments were made for the four predefined 
baseline variables of age, sex, body mass index, and duration of symptoms. 
Additionally, we adjusted for the stratification factor (ankle activity score).30 Outcomes 
of the generalised estimation equations model are presented as estimated means, 
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unless otherwise stated. The same method was used to evaluate most of the 
secondary outcomes (see web appendix 2). A Fisher’s exact test was used to evaluate 
only patient satisfaction, return to sport, and the patient acceptable symptom scale. 
The outcomes to evaluate the success of the procedures were analysed using 
a Fisher’s exact test or χ2 test (categorical outcomes) or unpaired t-test or Mann-
Whitney U-test (continuous outcomes).  We considered differences of P<0.05 to be 
statistically significant. Missing data were not imputed, but we would have carried out 
sensitivity analyses if missing data exceeded 5%. 
Patient and public involvement
Patients were not involved in defining the research question. Two patients participated 
in a pilot test round to evaluate the impact of the placebo and high-volume injection 
procedure. Patients were not involved in other aspects of the study design. After 
completion of the trial, all trial participants were contacted to evaluate relevant 
outcome measures and the burden of participation to improve future trials. Five 
patients took part in a patient meeting to discuss these items. Study results will be 
disseminated to the trial participants by email or letter.
Results
From December 2016 to January 2019, 185 patients with posterior ankle pain were 
screened for eligibility. After exclusions 80 participants were included in the study 
and randomised to either a high-volume injection without corticosteroids or a saline 
injection (placebo group). At the 24 week endpoint, only one participant was lost to 
follow-up (1%). Figure 1 shows the flow of participants through the trial. No differences 
in baseline characteristics were found between the groups, except for the presence 
of bilateral symptoms (table 1). A higher proportion of participants in the high-volume 
injection group had bilateral symptoms (17/39 (44%) v 11/41 (27%)). An additional 
analysis using a generalised estimation equations model was done to correct for the 
variable unilateral or bilateral symptoms.
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Figure 1. Flow of patients through study.
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Table 1. Baseline characteristics of adults with chronic midportion Achilles tendinopathy 
assigned to a high-volume injection without corticosteroid or placebo injection. Values are 




group (n= 41) 
Mean (SD) age (years) 46.9 (8.1) 48.9 (9.9)
Men 17 (44) 22 (54)
Mean (SD) body mass index 26.8 (5.7) 27.6 (5.1)
Activity level1
   Active in sports





Participation in desired sport (total 
hours per week)
3.9 (2.0) 4.9 (3.6)
Affected side
   Unilateral, left/right 





Median (interquartile range) duration 
of symptoms (weeks)
64 (17-112) 60 (14-107)
Mean (SD) VISA-A score 44.4 (15.5) 41.0 (16.0)
Interventions at study start 
   None
   Night splint
   Foot orthoses
   Pain killers












   Intratendinous





VISA-A, Victorian Institute of Sports Assessment-Achilles    
1 Determined using the ankle activity score. Participants who scored ≥4 points were considered to be active in 
sports (starting from physical work). Participants who scored ≤3 points were considered to be sedentary (cycling, 
equestrian, or less activity). Level of sport and sports participation is only presented for the active group.
Outcome measures
VISA-A score: In the high-volume injection group the estimated mean VISA-A score 
improved from 40.4 (95% confidence interval 32.0 to 48.7) at baseline to 59.1 (50.4 to 
67.8) at 24 weeks and in the placebo group from 36.9 (27.1 to 46.8) to 58.5 (47.9 to 
69.1). The interaction term treatment group×time point was not statistically significant 
(P=0.42), meaning that the VISA-A score did not differ over time between the groups. 
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The adjusted between group difference in VISA-A score at 24 weeks was 0.5 (95% 
confidence interval −17.8 to 18.8) in favour of the high-volume injection group (table 
2). Improvement in VISA-A score was not significant at two weeks for either group. 
VISA-A scores improved significantly in both groups at six weeks (P=0.05) and at 12 
and 24 weeks (P<0.01). Figure 2 presents the raw VISA-A scores. In the sensitivity 
analysis using the additional generalised estimation equations model to correct for 
unilateral or bilateral symptoms, the results for the primary outcome (interaction 
term treatment group×time point, P=0.44) remained unchanged.
Figure 2. Between group differences in Victorian Institute of Sports Assessment-Achilles (VISA-A) 
score from baseline in participants treated with a high-volume injection without corticosteroids 
































Table 2. Primary and secondary outcome measures in adults with chronic midportion Achilles 
tendinopathy assigned to a high-volume injection without corticosteroid or placebo. Values are 
numbers (percentages) unless stated otherwise









Estimated mean (95% CI) 
VISA-A score at follow-up 
(weeks)1
2 weeks 41.4 (33.7 to 49.1) 38.2 (28.3 to 48.1) 3.2 (-11.2 to 17.5)
6 weeks 43.3 (34.6 to 52.0) 46.1 (35.7 to 56.6) -2.8 (-18.9 to 13.3)
12 weeks 50.9 (42.3 to 59.5) 49.6 (39.3 to 60.0) 1.3 (-14.7 to 17.3)
24 weeks 59.1 (50.4 to 67.8) 58.5 (47.9 to 69.1) 0.5 (-17.8 to 18.8)
Secondary outcome measures
Patient satisfaction2
Moderate or poor 16 (43) 20 (51)
Excellent or good 21 (57) 19 (49)
HVI group (n=29) Placebo group 
(n=31)
Return to sport3
No return to sport 9 (31) 7 (23)
Returned to sports, 
but not to desired 
type
5 (17) 5 (16)
Returned to the 
desired sport, but not 
at pre-injury level
11 (38) 14 (45)
Returned in the 
desired sport at pre-
injury level
4 (14) 5 (16)
VISA-A, Victorian Institute of Sports Assessment-Achilles.
1Scores and adjusted between group differences were calculated using a generalised estimation equations 
model with adjustments for predefined baseline variables: age, sex, body mass index, duration of symptoms, 
and ankle activity score. Positive values favour the high-volume injection group. No statistically significant 
differences were found between the treatment groups at any time point.
2For analysis purposes, good or excellent patient satisfaction was dichotomised as “satisfied,” and a poor or 
moderate satisfaction as “dissatisfied.” Two patients in each group did not return the questionnaire in which 
patient satisfaction was assessed. No statistically significant differences were found between the treatment 
groups at 24 weeks (P=0.50).
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3 Number represents the proportion of participants who were active in sports before the study start (n=31 
in the high-volume injection group and n=33 in the placebo injection group). Two patients in each group did 
not return the questionnaire in which return to sport was assessed. Return to sport was dichotomised as 
“no return to desired sport” (no return to sport or return to sport, but not in the desired sport) or “return to 
desired sport” (regardless reaching pre-injury level). No statistically significant differences were found between 
both treatment groups at 24 weeks (P=0.65).
Patient satisfaction: No significant difference was found in patient satisfaction between 
the treatment groups at 24 weeks (P=0.50). In the high-volume injection group, 21/37 
patients (57%) reported an excellent or good outcome compared with 19/39 (49%) in 
the placebo group.
Return to sport: No significant difference was found for return to the desired sport at 
24 weeks (P=0.65). In the high-volume injection group, 15/29 (52%) patients returned 
to their desired sport compared with 19/31 (61%) in the placebo group. Of these 
participants, only 4/29 (14%) returned to their pre-injury level in the high-volume 
injection group and 5/31 (16%) in the placebo group.
Web appendix 2 shows the results of the other secondary outcome measures. No 
significant between group differences were found for any of these outcome measures.
Success of procedures
Success of the injection procedure on Doppler flow: In participants with intratendinous 
Doppler flow before the injection procedure (n=33 in the high-volume injection 
group and n=37 in the control group; table 1), Doppler flow was no longer detectable 
inside the Achilles tendon in 26/33 patients (79%) in the high-volume injection group 
compared with 11/37 patients (30%) in the control group (P<0.001). The disappearance 
of Doppler flow after the high-volume injection did not appear to influence the course 
of the VISA-A score over time compared with the presence of Doppler flow after the 
high-volume injection (P=0.99), as explained in detail in web appendix 4.
Success of patient blinding: In the high-volume injection group, 25/39 patients (64%) 
correctly thought they had received the high-volume injection. In the placebo group, 
22/41 patients (54%) correctly thought they had received the placebo injection 
(P=0.36).
Complications/pain during injection procedure: No complications (infections, 
haematomas, or tendon ruptures) were reported during the study period. The 
median pain score (visual analogue scale score 0-10) during the injection procedure 
was 6.0 (interquartile range 5.0-8.0) for the high-volume injection group and 5.0 (2.0-
7.0) for the placebo group (P=0.10).
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Adherence: 80% of participants (1536 out of 1920 questionnaires) completed the 
weekly online questionnaires to evaluate adherence to exercise treatment. The 
median percentage of performed exercises (compared with the amount of prescribed 
exercises) was 76% (interquartile range 46-100%) in the high-volume injection group 
and 72% (43-100%) in the placebo group (P=0.17).
Co-interventions: The use of 12 co-interventions (eg, foot orthoses, manual treatment, 
and sports massage) was reported in 12 patients (31%) in the high-volume intervention 
group compared with nine co-interventions in six patients (15%) in the placebo group 
(P=0.30).
Discussion
In our patient and assessor-blinded, placebo-controlled randomised clinical trial we 
found that a high-volume injection without corticosteroids has no added value to 
an exercise programme in patients with chronic midportion Achilles tendinopathy. 
We found no differences in patient-reported outcomes between the high-volume 
injection and a placebo injection. Also, no between-group differences were found in 
any of the secondary outcome measures, indicating that a high-volume injection does 
not have mechanistic effects.
Clinical implications
These findings are important and clinically relevant, as high-volume injections 
have become increasingly popular after several non-blinded case-series and one 
cohort study showed an improvement in pain during activities at intermediate-term 
follow-up (30-52 weeks).14 18 31 These findings exceeded the improvement known 
from eccentric exercises.24 32-34 As previous high-volume injection studies were only 
performed in non-responders to eccentric training, this treatment gained even more 
attention. Surprisingly, large improvements (38 points on the VISA-A score) after a 
high-volume injection were already seen in the short-term (three weeks).17 This 
indicates a rapid decrease in symptoms of Achilles tendinopathy when a high-volume 
injection is given. A recent blinded randomised controlled trial with a small sample 
size (n=19 in each treatment group) confirmed these findings, in which patient-
reported outcomes improved significantly more in the high-volume injection group 
at the six week follow-up compared with the placebo group. This improvement had 
slightly decreased at the 24 week follow-up. Improvement in VISA-A score was lower 
than expected in the placebo group at 24 weeks, thereby raising the possibility of 
unsuccessful blinding of the participants.16 23 35 36 In our large study, we did not find any 
beneficial effect of the high-volume injection in either the short-term (2 or 6 weeks) 
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or the intermediate-term (12 or 24 weeks). An important difference between our 
study and previous studies investigating high-volume injections, is that we did not use 
corticosteroids in the injection mixture. The hypothesis is that the saline solution in 
the injection mechanically damages the neovascularisation and its adjacent nerves.14 
Corticosteroids are discouraged as treatment for tendinopathies owing to detrimental 
long-term effects and the risk of ruptures of the Achilles tendon.37-39 Therefore, we 
decided not to include corticosteroids in the injection mixture. This could explain the 
difference in outcomes between our study and previous studies. We hypothesise that 
a high-volume injection does not have a mechanical pain-reducing effect, but that the 
short-term improvement as seen in previous studies might have been related to the 
corticosteroids. The previous randomised controlled trial evaluating the high-volume 
injection supports this hypothesis, since short-term outcome exceeded the long-term 
outcome. This is a typical course after treatment with a corticosteroid injection.40 In 
studies that did not use corticosteroids in the injection mixture, comparable results 
to ours were seen at 12-24 weeks.15 19 31 The clinical improvement in symptoms of 
Achilles tendinopathy for both treatment arms in our study is similar to that reported 
in a recent meta-analysis evaluating the effectiveness of treatment using heavy-load 
eccentric calf muscle exercise therapy and in a comparable population included at 
our research centre in which standalone exercise was provided.28 41 The difference in 
the form of exercise programmes is not likely to have influenced the results, because 
no evidence suggests that one form of exercise training is superior to another.42 
Improvement could additionally be explained by the placebo effect, patient education, 
load management, and the clinical course of the disorder. Our findings indicate that 
an exercise programme, patient education and load management are still beneficial 
in patients with no previous improvement during calf muscle exercise training. We 
would therefore advice all patients to continue an exercise programme as the basis 
of their treatment. 
Strengths and limitations of this study
The strength of our study is that we performed this randomised clinical trial according 
to the current consolidated standards of reporting trials (CONSORT) guideline. The 
patients, outcome assessor, and statistician were all blinded to the intervention, and 
only one participant was lost to follow-up. Despite our robust research design, our 
study also has some methodological limitations. Firstly, it was not feasible to blind 
the doctor who performed the injection procedure at baseline. As this doctor was 
not involved in the treatment allocation (randomisation), follow-up of participants, 
or data analysis, this probably did not influence study outcomes. Secondly, the lack 
of a group that only performed an exercise programme (without injection) might 
be regarded as limitation. We do not know whether the improvement of symptoms 
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over time in both groups is a consequence of the exercise programme, a promoted 
healing response after the injection procedure, a placebo effect from the injection 
procedure, or represents the clinical course of Achilles tendinopathy. Thirdly, a high-
volume injection is a technically demanding and specific procedure. A single sports 
medicine doctor with extensive experience in injection procedures performed the 
interventions. Test sessions were carried out before the start of the study according to 
instructions provided by experts in high-volume injections.14 Intratendinous Doppler 
flow disappeared in 79% of the patients in the high-volume injection group compared 
to 30% in the placebo group, indicating success with the high-volume injection. 
Conclusion
In patients with a chronic midportion Achilles tendinopathy, a high-volume injection 
without corticosteroids did not result in a beneficial effect in addition to an exercise 
programme. On the basis of these findings, we cannot recommend the use of a high-
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Since the year 2000 there is an exponential increase in publications regarding Achilles 
tendinopathy; currently more than a hundred studies each year are being published. 
Knowledge is increasing rapidly, however, literature is often inconclusive, and many 
questions remain unanswered. The general aim of this thesis was to evaluate risk 
factors, to study imaging with a focus on Doppler flow, and analyse treatment options 
in patients with Achilles tendinopathy.
Risk factors
The identification of risk factors for Achilles tendinopathy is of great importance, 
as basis for future primary prevention and treatment strategies. We identified the 
following nine risk factors for Achilles tendinopathy in our systematic review: a history 
of a lower limb injury, season of training, calf muscle strength, gait analysis parameters, 
moderate alcohol use, fluoroquinolone antibiotic treatment and suboptimal renal 
function in a specific heart transplant population.1-6 High-quality prospective cohort 
studies investigating risk factors were unfortunately missing and most studies 
investigated a non-representative young population (median age 21 years), thereby 
resulting only in limited evidence for all risk factors. 
An important risk factor for Achilles tendinopathy seemed to be a history of a lower 
limb injury, with an odds ratio of 4 in a single study.3 In this study, 146 participants (2.1%) 
developed Achilles tendinopathy during a one year follow-up period in a population 
of 7,113 participants with a history of lower limb injury. In the 70,790 participants 
with no history of lower limb tendinopathy, only 304 participants (0.4%) developed 
symptoms. The relationship between the time that one has been asymptomatic, and 
the risk of developing Achilles tendinopathy has not been reported in this study for the 
group with a history of lower-limb injury. Most likely the risk for recurrent symptoms 
will be highest in patients that recently became asymptomatic. Unfortunately, this 
risk factor is not modifiable and cannot serve in future primary preventive strategies. 
Based on our results, we would advise patients that are at risk to develop Achilles 
tendinopathy to: (1) reduce the use of alcohol to a maximum of 7 units per week for 
men and 4 units for women, (2) avoid the use of ofloxacin if alternatives are available, 
and (3) improve plantar flexor strength by performing strengthening exercises of the 
calf muscles.1 3 6 
Whether these preventive interventions are effective for Achilles tendinopathy is 
uncertain. Of our advices, only strengthening exercises of the calf muscles as preventive 
strategy have been investigated.7 There was no preventive effect when performing 
these exercises in a group of professional soccer players. The discrepancy between 
the risk factor and the preventive effect could be explained by the low compliance 
(only 2 sessions per week were performed) and that no additional weights were used 
during the performance of the exercises.8 Exercises were also performed in-season, 
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whereas it could be hypothesised that strengthening exercises are more effective 
when performed in the pre-season to gradually increase musculoskeletal load. 
We demonstrated in our systematic review that there is currently no evidence for 
an association between physical activity level and Achilles tendinopathy. However, 
previous risk factor studies measured the absolute load and sudden changes in 
load could be more important. Recent studies in team sports and endurance sports 
showed that the overall injury rate is increased when there are rapid increases in 
training load.9 10 This has been analysed using the acute:chronic workload ratio. In this 
ratio, the ‘acute’ training load is the load of a certain week (e.g. kilometres per week 
in runners), which is divided by the ‘chronic’ load (e.g. average kilometres per week in 
the previous four weeks). When the training load is almost equal every week, the ratio 
is approximately 1. An acute:chronic workload ratio of ≥1.5 increases the injury risk in 
the following week.9 10 We recommend future risk factor research in this field to focus 
on changes in load, rather than the absolute load at one moment in time. Besides, 
physical activity level could have been measured not accurately enough to detect 
associations, as previous studies investigated hours of training or training distance 
as risk factor. The recent introduction of wearables in sports and tracking apps could 
prove useful in future studies. Parameters such as speed, cadence, step length, 
number of accelerations, and number of high-intensity sprints should be included 
when analysing change in physical activity level. 
Training season and gait analysis parameters have both only been investigated in one 
relatively small cohort study.2 4 Also, in both studies several important confounders 
could have been present. In the study analysing gait parameters the gait pattern 
was determined barefoot, whereas running shoes are likely to influence the gait 
pattern. Furthermore, two studies investigating the preventive effect of shoe orthoses 
did not demonstrate a risk reduction for developing Achilles tendinopathy.11 12 It 
should, however, be noted that the number of cases (resp. 2 and 12 cases) in these 
studies were too low as 20-50 cases are necessary to detect moderate to strong 
associations.13 In the study investigating training season as risk factor, temperature 
and type of surface when training could have been important confounders for this 
risk factor. As a result, both risk factors do not result in clinical implications. 
Overweight is generally defined by clinical experts as important risk factor for Achilles 
tendinopathy. The hypothesis for the relationship between body weight and Achilles 
tendinopathy is primarily based on an increase in absolute tendon load, but also 
on increased cytokine levels (Prostaglandin E2, tumour necrosis factor-alfa and 
Leukotriene B4) that have been demonstrated to cause a low-grade inflammation.14 
15 Interestingly, we did not find evidence that overweight is associated with Achilles 
tendinopathy.1-4 16 17 We cannot exclude a relationship, as the majority of the 
studies investigated an adolescent population in which overweight is less common. 
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Therefore, cohort studies are warranted in more heterogeneous populations. These 
studies should include the fat percentage as outcome measure. BMI that is most 
often investigated could be considered inaccurate in athletes, as an increased muscle 
mass could also lead to an increased BMI.18 
Imaging; a focus on neovascularisation and its role in pain sensation
Doppler flow (neovascularisation) around and within the tendon is a characteristic 
feature in patients with longstanding symptoms of Achilles tendinopathy.19-23 Nerve 
structures present alongside the neovascularisation suggest that the tendon tissue 
will be more susceptible for stimuli such as nociceptive pain. The amount of Doppler 
flow have been determined in previous studies using the modified Öhberg score, 
which exceeded the reliability of the original Öhberg score.24 This modified Öhberg 
score is a semi-quantitative scoring system, which runs from 0-4+ (higher scores 
indicate more evident Doppler flow).20 25 26 Inter-observer reliability varies from 
moderate to almost perfect, however, important disadvantages have been described 
as the scoring system in not able to distinguish higher amounts of Doppler flow (ceiling 
effect) and is less sensitive to detect changes.24 26-29 As a result, novel quantitative 
scoring systems were warranted. 
We investigated whether the quantification of coloured pixels of the Doppler flow 
is reliable. In this method, the percentage of colour pixels is determined within the 
Achilles tendon and/or the peritendinous region. This is called the surface area 
quantification (SAQ) method, which was first introduced by Boesen et al.30 31 The 
reliability had, however, not been tested before commencement of our study. We 
demonstrated that the SAQ method is a reliable measurement tool in a patient group 
with longstanding symptoms of midportion Achilles tendinopathy (ICC 0.81). Reliability 
is as good as that of the modified Öhberg score, but it clearly overcomes the ceiling 
effect of the modified Öhberg score by differentiation between high amounts of 
Doppler flow. This is a prerequisite for its application in future research.24 26 29 
 
Treatment modalities
A myriad of treatment modalities for Achilles tendinopathy have been investigated 
the last decades, including wait-and-see, exercise therapy, injections, shockwave 
therapy, orthosis, medication, and surgery. To compare the effectiveness of different 
treatment modalities, it is important to have knowledge of the minimal clinically 
important difference (MCID) of an outcome measure. In our randomised clinical trial, 
we used the generally accepted Victorian Institute of Sports Assessment-Achilles 
(VISA-A) questionnaire to assess the effectiveness of the treatment.32 33 Previous 
research in patients with midportion Achilles tendinopathy showed a very wide 
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range of 6.5 to 25 points for the MCID of the VISA-A.34-37 These studies used a purely 
statistical approach to determine the MCID, thereby lacking a link with the difference 
that is clinical meaningful according to patients.
We determined the MCID in the population of the randomised clinical trial, in which 
patients were asked to rate the improvement/worsening of their symptoms using a 
global assessment scale.35 Using this scale, we were able to determine the MCID using 
an anchor-based approach. This approach connects the subjective assessment of the 
patient to a numerical score such as the VISA-A score.38 Previous studies most often 
used a distribution-based approach to determine the MCID, which lacks a clinical 
relevance for the patient as subjective assessments such as the global assessment 
scale are not included in this approach. We demonstrated that the MCID for the 
VISA-A score was 14 points in patients with longstanding symptoms of midportion 
Achilles tendinopathy after three months of conservative treatment or 7 points after 
six months of conservative treatment. Our sample size to determine the MCID for 
the VISA-A score was the largest to date, and we were the first study to differentiate 
between different timepoints. There was, however, a large difference of the MCID for 
the VISA-A score at 3 and 6 months (14 points at 3 months, 7 points at 6 months). 
This could be explained by recall bias; patients could have remembered symptoms 
to be worse than they actually were with subjective improvement as a consequence. 
Interpretation of data using the MCID should, therefore, always be done with caution. 
Almost all studies included in our systematic review and network meta-analysis 
investigated a population with midportion Achilles tendinopathy; there is a lack of 
studies investigating a population with insertional Achilles tendinopathy. The most 
striking finding was that none of the current randomised clinical trials was at low 
risk of bias, and the effectiveness of the treatments showed large uncertainties 
in their estimates. The main finding was that active treatments seemed to have 
patient-important benefits at 3-month follow-up compared to a wait-and-see policy. 
All treatment modalities showed superiority to wait- and-see treatment, with most 
studies exceeding the MCID of 14 points. In other words, it is better to do something 
than do nothing. It should be noted that wait-and-see treatment has only been 
investigated in a single trial and data is, therefore, not robust. Also, the wait-and-see 
approach is questionable as an appointment with an orthopaedic surgeon was made 
with discussion of training modifications, implementation of stretching exercises, and 
ergonomic advices.39 We feel, however, that based on current evidence it would not 
be ethical to include a pure wait-and-see approach as treatment arm in future trials. 
But what is the most effective treatment if healthcare professionals want to actively 
treat Achilles tendinopathy? Two classes showed superiority in our network meta-
analysis: Acupuncture therapy and shockwave therapy combined with exercise 
therapy.40 41 These results were, however, based on two small trials (64 and 68 included 
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patients respectively) that were both at high risk of bias. We feel that there is too 
much uncertainty to explicitly support these as treatments of first choice. As all active 
treatments had overlapping comparative effects, we concluded that there was no 
evidence of a clinically relevant difference in effectiveness between the different active 
treatments at 3-month and 12-month follow-up. Shared decision making should play 
an important role when managing a patient with Achilles tendinopathy, considering 
the safety profile, treatment availability, and costs. In the absence of convincing 
evidence to support a specific treatment modality, we favour calf-muscle exercise 
therapy as treatment of first choice. Exercise therapy is suggested to be cheap, is 
available everywhere and has a low risk of harm.42 43 Exercise therapy in general is 
recommended, as no specific type of exercise therapy has shown superiority over 
one another in the available trials.44The effectiveness of most active treatments in the 
long term (beyond 6 months) is uncertain. At 12 months, we did not find a difference 
between exercise therapy, injection therapies, and combined therapies. Also, our 
recommendations focus on patients with longstanding (>3 months) symptoms of 
midportion Achilles tendinopathy, as literature in patients with short living symptoms 
(<6 weeks) and insertional tendinopathy is extremely limited.45 
Most available treatments in the network meta-analysis, such as injection therapies, 
exercise therapy, and surgery, are focusing on restoring the structure of the Achilles 
tendon. It has, however, been demonstrated that improvements in pain and function 
were not associated with improvements in tendon structure.46 As a result, novel 
treatment modalities have been introduced with the aim to intervene on other 
aspects of the pathophysiological model in Achilles tendinopathy. An example of such 
a treatment option in midportion Achilles tendinopathy is the high-volume injection. 
As stated earlier, the aim of this injection technique is to obliterate the peri- and 
intratendinous neovascularisation and adjacent nerve structures that are present in 
Achilles tendinopathy through a high mechanical pressure.47 48 This is expected to 
affect local pain processing. The technique has become increasingly popular after 
several case-series demonstrated a clinically relevant improvement in symptoms at 
both short-term and intermediate-term follow-up period.47 49 50 A recent blinded RCT 
with small sample size (N=19 per intervention group) confirmed these findings, but 
robust evidence was still missing.51 Contrary to previous findings, we demonstrated in 
our patient and assessor-blinded, placebo-controlled randomised clinical trial that a 
high-volume injection is not effective for symptom reduction in addition to usual care 
for patients with chronic midportion Achilles tendinopathy. 
A crucial difference between our trial and previous studies is that we did not use 
corticosteroids in our injection mixture. We excluded corticosteroids as these do 
theoretically not affect the mechanical effect of the high-volume injection. Also, there 
is an increased risk of Achilles tendon ruptures following a corticosteroid injection 
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and corticosteroids are known to have detrimental long-term effects.52-54 Most likely 
previous studies did not demonstrate the effectiveness of the high-volume injection 
procedure, but instead they demonstrated a pain-reducing short-term effect caused 
by the corticosteroids in the injection mixture. In the previous randomised clinical 
trial short-term outcome exceeded the intermediate-term outcome, which is a typical 
course following a corticosteroid injection.51 52 Also, our ultrasonographic findings 
demonstrated that the degree of neovascularisation already returned to pre-injection 
levels only one hour after the injection procedure. This makes a mechanical effect of 
the high-volume injection itself unlikely. 
Patients in both the high-volume injection group and the placebo group of the 
randomised clinical trial demonstrated significant improvements in pain and function 
over a 24-week follow-up period. The improvement in VISA-A score was approximately 
20 points at 24 weeks follow-up, which is comparable with previous results in heavy-
load eccentric calf muscle exercise therapy as standalone treatment.42 Therefore, 
we advise all patients to continue exercise therapy as basis of their treatment. 
Patient education and load management could additionally play an important role 
in the improvement of symptoms over time, as these are usually incorporated 
in all investigated treatment options. This has also been the case in our study. To 
date, patient education and load management has not been studied as standalone 
treatment and should, therefore, be considered an addition to the exercise therapy. 
We also used the SAQ method to explore the mechanical effect of a high-
volume injection. The aim of this injection technique is to obliterate the peri- and 
intratendinous neovascularisation and adjacent nerve structures that are present in 
Achilles tendinopathy through a high mechanical pressure.47 Directly following both 
injection procedures in our study, Doppler flow decreased from 4.8% to 0.1% in 
patients receiving a high-volume injection and from 5.4% to 2.0% in the placebo group 
with no significant difference between both study groups (between-group difference 
1.9%, 95% CI -1.2 to 4.9%). Interestingly, one hour after the injection procedure the 
amount of Doppler flow returned to pre-injection levels in both study groups. This 
strongly suggests an absence of mechanical destruction of neovascularisation as 
a result of a high-volume injection. The decrease in Doppler flow directly after the 
intervention is more likely explained by inactivity during the injection procedure, as 
activity has been found to influence Doppler flow.31 From 2 to 24 weeks follow-up, 
there was no significant change in Doppler flow in both study group. This is in line with 
two previous studies in which no clinically relevant difference was present during a 3 
to 24 week follow-up period following a high-volume injection.51 55 Both studies used 
the modified Öhberg score as outcome measure. 
The association between Doppler flow and patient reported outcomes (e.g. VISA-A 
score) was of interest in the last decade. Previous studies measuring Doppler flow using 
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the modified Öhberg score demonstrated that a decrease in Doppler flow was not 
associated with an improvement in the patient reported VISA-A score.19 25 Despite our 
surface area quantification overcoming limitations of the modified Öhberg score, an 
association between Doppler flow and patient reported outcome was still absent. We 
also demonstrated that quantified Doppler flow is no prognostic indicator of recovery, 
which is in line with two previous studies applying semiquantitative measures.20 23 This 
further questions the clinical importance of neovascularisation in tendinopathy.
Pain processing is of increasing interest in tendinopathy. As stated earlier, the severity 
of tendon disorganisation is not directly related to the degree of pain.56 57 Peripheral 
pain due to local tissue damage of the Achilles tendon is, therefore, considered not 
to be the only driver of pain sensation. Central pain processing has been found 
to be altered in patients with Achilles tendinopathy, causing pathophysiological 
pain (central sensitisation).58-60 This could explain why some patients with Achilles 
tendinopathy do not respond to most treatments that are tissue-based. Isometric 
exercises of several muscle groups (e.g., quadriceps muscles) have been found to 
influence central pain processing.61 62 Since 2015, isometric exercises gained a lot 
of attention after one study demonstrated a large and meaningful decrease in pain 
score following isometric exercises of the quadriceps femoris in patients with patellar 
tendinopathy.63 Despite this being the only study and the very small sample size of 
only 6 participants, isometric exercises were implemented rapidly for immediate 
pain relief. Subsequently, results were quickly extrapolated to other tendinopathies 
such as Achilles tendinopathy. We demonstrated that neither isometric exercises nor 
isotonic exercises provided immediate pain relief in patients with chronic midportion 
Achilles tendinopathy. Recent studies in patients with lateral elbow tendinopathy, 
plantar fasciopathy, and patellar tendinopathy also reported no meaningful change 
in pain scores after the performance of isometric exercise.63-65 Thereby, there seems 
to be no longer any ground to assume that isometric exercises provide immediate 
pain relief. Both isometric and isotonic exercises were well tolerated in our study and 
could still be considered a starting point for exercise therapy. 
Future perspectives
Several aspects in the field of Achilles tendinopathy have been extensively discussed 
in this thesis, yet some questions remain unanswered and new questions arose. We 
feel that future research should focus on the following topics: 
General perspectives
One of the main problems in the field of Achilles tendinopathy is the lack of consensus 
regarding core outcome measures. There is currently an international consensus 
to agree on these outcome measures. These results will, hopefully, improve 
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comparability of future trials. Furthermore, several subtypes of Achilles tendinopathy 
based on location of the symptoms (insertional/midportion Achilles tendinopathy) 
and duration of symptoms (reactive/chronic Achilles tendinopathy) are often not 
taken into account when designed trials. Future trials should specify their population 
to include a homogeneous population. 
Risk factors
More adequately powered and designed prospective cohort studies are needed to 
investigate risk factors for Achilles tendinopathy. We would specifically recommend 
investigating changes in training load (e.g. acute:chronic workload ratio), plantar flexor 
strength, and fat percentage as potential risk factors for Achilles tendinopathy. These 
potential risk factors should be investigated in a heterogeneous population in which 
Achilles tendinopathy is most common (mean age 40-60 years old). These future risk 
factors could be used for designing preventive strategies. 
Imaging; a focus on neovascularisation and its role in pain sensation
We feel that the surface area quantification method is adequate and reliable to detect 
Doppler flow in Achilles tendinopathy. We advise future trials to use this method to 
evaluate Doppler flow in Achilles tendinopathy, especially when treatment options 
target neovascularisation in Achilles tendinopathy. 
Treatment modalities
First, there remains uncertainty in the treatment modality that should be advised 
as first line therapy in patients with Achilles tendinopathy. Most clinicians feel the 
urge to actively treat the disorder, however patient education and load management 
have never been examined as sole treatments. Also, research in insertional Achilles 
tendinopathy and patients with recent symptoms (<6 weeks) of Achilles tendinopathy 
is extremely limited. Especially research in patients with recent symptoms is warranted, 
as this could potentially contribute to prevent chronic symptoms in patients with 
Achilles tendinopathy. Future studies should be adequately powered and designed, 
using outcome measures from the current consensus procedure as described in the 
general future perspectives. As our systematic review and network meta-analyses has 
a ‘living’ design, we will update the analyses and publish the results when there are 
important changes that affect clinical care. Future research could provide insights 
to individualise treatment in patients with Achilles tendinopathy. Therefore, large 
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The general aim of this thesis was to evaluate risk factors, imaging, and treatment 
options in patients with Achilles tendinopathy. In Chapter 1 an overview of the current 
literature has been given including risk factors to develop Achilles tendinopathy, 
imaging with a focus on ultrasonographic Doppler flow, and the available treatment 
options for Achilles tendinopathy. 
Risk factors
In Chapter 2 we performed a systematic literature review to identify risk factors for 
Achilles tendinopathy. Unfortunately, there appeared to be a lack of high-quality 
prospective studies that identified these potential risk factors. We found limited 
evidence for nine risk factors for Achilles tendinopathy: a history of lower limb 
injury, season of training, calf muscle strength, gait analysis parameters, moderate 
alcohol use, fluoroquinolone antibiotic treatment, and suboptimal renal function in a 
specific heart transplant population. As a result, we feel healthcare providers could 
advice all patients to: (1) reduce the use of alcohol to less than 7 units per week for 
men and less than 4 units for women, (2) avoid the use of ofloxacin if alternatives 
are available and (3) improve plantar flexor strength by performing strengthening 
exercises of the calf muscles. More high-quality research in this field is warranted, as 
modifiable determinants could prove useful for prevention and treatment of Achilles 
tendinopathy. 
Imaging; a focus on neovascularisation and its role in pain 
sensation 
Neovascularisation, one of the features during ultrasonography in patients with 
Achilles tendinopathy, is of increasing interest in this patient group. Most often the 
neovascularisation is evaluated using the modified Öhberg score, however, this 
score has several limitations in a research setting.  In Chapter 3 we evaluated the 
inter-observer reliability of a relatively novel surface area quantification method. 
Two observers examined the degree of Doppler flow independently during a 
single consultation. Both the most frequently used modified Öhberg score (a semi-
quantitative score) and the surface area quantification method (a quantitative score) 
were determined. We included 28 consecutive patients with chronic midportion 
Achilles tendinopathy. We demonstrated that our surface area quantification method 
has a good reliability to evaluate the degree of Doppler flow in this patient group. 
When compared to the modified Öhberg score, the surface area quantification 
method is a fully quantitative score, at least as reliable as the modified Öhberg score 
and it overcomes the ceiling effect of the modified Öhberg score by differentiating 
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high amounts of Doppler flow. We advise using this quantitative measurement for 
research purposes to determine the degree of Doppler flow in patients with chronic 
midportion Achilles tendinopathy. 
Treatment
Treatment effectiveness for patients with Achilles tendinopathy is currently most 
often evaluated using the validated and disease-specific Victorian Institute of Sports 
Assessment-Achilles (VISA-A) questionnaire. The VISA-A questionnaire evaluates 
Achilles tendon pain, function, and activity level. There was, however, much uncertainty 
regarding the change in VISA-A score that is clinically meaningful for patients and at 
what VISA-A score patients consider symptoms to be acceptable. In Chapter 4 we 
determined the minimal clinically important difference (MCID) and patient acceptable 
symptom state (PASS) of the VISA-A score in patients with chronic midportion 
Achilles tendinopathy. This study was part of the randomised clinical trial in which 
the effectiveness of a high-volume injection was evaluated. We demonstrated that a 
change in VISA-A score of 14 points reflects a meaningful change after 12 weeks of 
conservative treatment. Patients consider symptoms to be acceptable from a VISA-A 
score of 60 points and above. This is important information for designing future 
studies in this field.
In Chapter 5 we evaluated the comparative effectiveness of all available treatments 
for Achilles tendinopathy in a living systematic review with network-meta-analysis. 
We included 29 randomised clinical trials, in which 42 different treatments were 
investigated. None of the trials was of low risk of bias, most had a short follow-up 
period of less than 6 months and there was large uncertainty in the comparative 
estimates. Active treatments seemed to be superior to a wait-and-see policy in 
patients with midportion Achilles tendinopathy at 3 months follow-up. There was no 
minimal clinically important difference between the different active treatments at 
3- and 12-months follow-up. We advise clinicians to start with calf-muscle exercise 
therapy as initial treatment, as this is easy to prescribe in clinical practice, is widely 
available, and is regarded as safe and cheap. Evidence for treatment effectiveness in 
insertional Achilles tendinopathy is very limited, thereby limiting conclusions for this 
subgroup. We will update this living systematic review regularly, which allows for a 
contemporary evidence synthesis for clinical practice.
Novel treatments for Achilles tendinopathy are being introduced continuously, but 
often scientific evidence for these treatments is missing. In Chapter 6, 91 patients 
were quasi-randomised to perform either isometric exercises (plantarflexed or 
dorsiflexed ankle position), isotonic exercises, or rest with the aim to evaluate the 
immediate analgesic effect of isometric exercises. We demonstrated that neither 
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isometric exercises nor isotonic exercises result in an immediate analgesic effect 
in these population of patients with chronic midportion Achilles tendinopathy. As a 
result, we do not recommend the performance of isometric exercises with the aim to 
provide immediate pain relief. 
Another very promising treatment seemed to be the novel high-volume injection, 
which aims to obliterate the neovascularisation that is frequently observed in Achilles 
tendinopathy. In Chapter 7 we investigated whether a high-volume injection improves 
clinical outcome in addition to usual care. We performed a stratified, patient and 
assessor-blinded, placebo-controlled randomised clinical trial, in which we included 
80 patients with chronic midportion Achilles tendinopathy. All patients performed 
a calf-muscle exercise program for 24 weeks (usual care) and were randomised to 
receive either a 50 ml high-volume injection or a 2 ml placebo injection. The injection 
mixture consisted of saline and lidocaine for both injections. We demonstrated that 
a high-volume injection does not provide a beneficial effect in addition to usual care 
in patients with chronic midportion Achilles tendinopathy, as no between-group 
differences were present. Based on this RCT, we do not recommend a high-volume 
as treatment in patients with chronic midportion Achilles tendinopathy. 
The surface area quantification method was subsequently used to explore the 
mechanism of a high-volume injection. In Chapter 8 we evaluated the ultrasonographic 
outcome measures of the randomised clinical trial in which the effectiveness of the 
high-volume injection was evaluated in patients with chronic midportion Achilles 
tendinopathy. We demonstrated that Doppler flow was not reduced at short or 
intermediate term follow-up following a high-volume injection, when compared to a 
placebo injection. A significant decrease was present directly after the high-volume 
injection procedure; however, this is most likely explained by inactivity as a similar 
decrease was seen following a placebo injection. Furthermore, Doppler flow returned 
to pre-injection levels one hour after the high-volume injection procedure. These 
findings challenge a mechanical effect of a high-volume injection. Additionally, we 
demonstrated that (1) baseline Doppler flow is not a prognostic indicator for patient 
reported outcome and that (2) changes in Doppler flow do not predict the course of 
symptoms over time. 
In Chapter 9 the main results of this thesis are described in relation to each other and 
the current scientific literature. Recommendation for future research are presented 














De achillespees is de grootste en sterkste pees van het menselijk lichaam, desondanks 
is een overbelasting blessure van de achillespees (achilles tendinopathie) een 
veelvoorkomende blessure. Het komt met name voor bij sporten waarbij er sprake is 
van hardloopbelasting, zoals hardlopen en voetbal. Bij recreatieve hardlopers heeft 
ongeveer 1 op de 12 hardlopers klachten van een achilles tendinopathie. Naarmate 
de sportbelasting verhoogd wordt neemt het risico verder toe; bij professionele 
hardlopers ontwikkelt zelfs de helft van de hardlopers achilles tendinopathie 
gedurende hun carrière. Ongeveer 1/3e van de patiënten is echter niet sportief 
actief, hierbij spelen waarschijnlijk andere factoren zoals genetisch profiel en 
lichaamssamenstelling een rol.  
Klachten bestaan voornamelijk uit pijn die optreedt bij belasting in het gebied van 
de achillespees. Daarnaast kan er sprake zijn van stijfheid van de achillespees in de 
ochtend, pijn bij aanraking van de achillespees en een zwelling van de achillespees. 
Klachten kunnen voorkomen in het middengedeelte van de achillespees (midportion 
achilles tendinopathie) of aan de aanhechting van de achillespees op het hielbeen 
(insertie achilles tendinopathie). Herstel duurt in veel gevallen lang en is hierdoor vaak 
frustrerend voor zowel de patiënt als de zorgverlener. Dit wordt mede veroorzaakt 
doordat onbekend is welke behandeling het beste werkt, waardoor vaak meerdere 
behandelingen achter elkaar uitgevoerd worden door patiënten.
 Het doel van dit proefschrift is om een bijdrage te leveren aan de kennis op het gebied 
van risicofactoren op het ontwikkelen van achilles tendinopathie, beeldvorming en 
behandelopties bij patiënten met achilles tendinopathie. 
In hoofdstuk 1 is een overzicht gegeven van de huidige literatuur op het gebied van 
achilles tendinopathie met de focus op risicofactoren, beeldvorming met de focus op 
echografie en behandelopties. 
Risicofactoren
In hoofdstuk 2 is een systematisch literatuuronderzoek uitgevoerd voor het 
identificeren van risicofactoren voor het ontstaan van een achilles tendinopathie. 
Op dit gebied was er sprake van afwezigheid van studies van hoge kwaliteit. We 
vonden beperkt bewijs voor negen risicofactoren voor het ontstaan van achilles 
tendinopathie: 1) Een eerder doorgemaakte tendinopathie van de onderste 
extremiteit, 2) trainen in de winterperiode, 3) een verminderde spierkracht van de 
kuitspieren, 4) een meer laterale voetafwikkeling, 5) een afgenomen voorwaartse 
progressie tijdens de propulsie fase bij een loopanalyse, 6) alcoholgebruik, 7) het 
gebruik van fluoroquinolonen-antibiotica, 8) het aantal weken dat dit gebruikt wordt 
en 9) een verminderde nierfunctie specifiek bij patiënten die een harttransplantatie 
hebben ondergaan. Op basis van deze bevindingen raden wij aan dat zorgverleners 
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patiënten dienen te adviseren om: 1) het gebruik van alcohol te reduceren tot minder 
dan 7 eenheden per week voor mannen en minder dan 4 eenheden voor vrouwen, 
2) het gebruik van ofloxacine (fluoroquinolone-antibioticum) te vermijden indien 
alternatieven beschikbaar zijn en 3) de spierkracht van de kuitspieren te verbeteren 
door krachtoefeningen uit te voeren. Aanvullend hoogkwalitatief onderzoek naar 
risicofactoren is zeer gewenst, omdat beïnvloedbare risicofactoren een bijdrage 
kunnen leveren aan het voorkomen van en de behandeling van achilles tendinopathie. 
Beeldvorming; een focus op neovascularisatie en de rol in pijnbeleving
Vaatnieuwvorming, in medische taal neovascularisatie genoemd, is één van de 
bevindingen tijdens echografisch onderzoek bij patiënten met achilles tendinopathie. 
De mate van neovascularisatie wordt van oudsher uitgedrukt in categorieën van de 
locatie en ernst van de neovascularisatie. Dit wordt gedaan middels de zogenaamde 
gemodificeerde Öhberg score. In hoofdstuk 3 hebben wij eerst de betrouwbaarheid 
van de relatief nieuwe oppervlakte kwantificatie methode beoordeeld die gebruikt 
kan worden om een score te hangen aan deze stromingen. Twee onderzoekers 
hebben voor deze studie de mate van Doppler flow onafhankelijk beoordeeld 
tijdens eenzelfde afspraak van een patiënt. Zowel de gemodificeerde Öhberg score 
(een semi-kwantitatieve schaal) die meestal gebruikt wordt in wetenschappelijk 
onderzoek om Doppler flow te beoordelen en de oppervlakte kwantificatie methode 
(kwantitatieve schaal) zijn verkregen. Er werden 28 patiënten met langdurige klachten 
van midportion achilles tendinopathie geïncludeerd. Wij hebben aangetoond dat de 
oppervlakte kwantificatie methode een goede betrouwbaarheid heeft om de mate 
van Doppler flow te evalueren in deze patiëntengroep. Wanneer deze methode 
vergeleken wordt met de gemodificeerde Öhberg score die tot op heden meestal 
gebruikt werd, is deze methode minstens zo betrouwbaar en beter in staat te 
differentiëren bij aanwezigheid van hoge waardes van Doppler flow. Wij adviseren om 
de oppervlakte kwantificatie methode te gebruiken bij toekomstig wetenschappelijk 
onderzoek waarin de mate van Doppler flow bepaald moet worden bij patiënten met 
langdurige klachten van midportion achilles tendinopathie. 
Behandeling
Effectiviteit van behandelingen voor patiënten met achilles tendinopathie wordt 
in de meeste gevallen beoordeeld middels de gevalideerde en ziekte-specifieke 
Victorian Institute of Sports Assessment-Achilles (VISA-A) vragenlijst. Deze VISA-A 
vragenlijst evalueert pijnklachten van de achillespees, functie van de achillespees en 
activiteitenniveau. Hieruit volgt een score, waarbij een score van 100 een volledig 
gezonde sporter reflecteert met een afname van de score bij toenemende klachten. 
Er was echter veel onzekerheid welke verandering in VISA-A score klinisch relevant 
is voor patiënten en bij welke VISA-A score patiënten hun symptomen acceptabel 
vinden. In hoofdstuk 4 hebben we het minimaal klinisch relevant verschil en het 
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niveau waarop patiënten hun symptomen acceptabel vinden bepaald bij patiënten 
met langdurige klachten van midportion achilles tendinopathie. Dit onderzoek was 
onderdeel van een gerandomiseerde klinische studie waarin de effectiviteit van een 
hoog-volume injectie is beoordeeld. We hebben aangetoond dat een verandering 
in VISA-A score van 14 punten klinisch relevant is na 12 weken conservatieve 
behandeling. Klachten zijn acceptabel voor patiënten vanaf een VISA-A score van 60 
punten. Dit is belangrijke informatie voor het opzetten van toekomstig onderzoek bij 
patiënten met achilles tendinopathie. 
In hoofdstuk 5 is een grote internationale studie beschreven waarin de effectiviteit 
van alle behandelopties voor achilles tendinopathie vergeleken zijn. Dit is gedaan 
middels een systematisch literatuuronderzoek en een zogenaamde netwerk meta-
analyse. In dit onderzoek zijn 29 gerandomiseerde klinische studies geïncludeerd, 
waarin in totaal 42 verschillende behandelopties onderzocht zijn. Geen van de 
studies had een laag risico op bias (vooringenomenheid), de meeste studies 
volgden patiënten voor een korte duur op (minder dan 6 maanden) en er was veel 
onzekerheid in de puntschattingen in de netwerk meta-analyse. Na 3 maanden leken 
actieve behandelopties effectiever te zijn dan een overwegend afwachtend beleid bij 
patiënten met midportion achilles tendinopathie. Er was geen sprake van een klinisch 
relevant verschil tussen de verschillende actieve behandelopties na respectievelijk 3 
en 6 maanden behandeling. Wij adviseren zorgverleners daarom om te starten met 
oefentherapie van de kuitspieren als initiële behandeling, omdat dit gemakkelijk voor 
te schrijven is in de kliniek, breed beschikbaar is en veilig en goedkoop wordt geacht. 
Wetenschappelijk bewijs voor de effectiviteit van behandelopties voor insertie achilles 
tendinopathie is uiterst beperkt, waardoor er geen conclusies kunnen worden gedaan 
voor deze groep patiënten. Dit onderzoek zal regelmatig een update krijgen bij het 
verschijnen van nieuwe relevante literatuur, om daarmee te zorgen voor handvaten 
voor zorgverleners. 
Nieuwe behandelopties worden regelmatig geïntroduceerd en toegepast, echter veelal 
ontbreekt wetenschappelijk bewijs voor het toepassen van deze behandelopties. In 
hoofdstuk 6 zijn 91 patiënten willekeurig verdeeld in 4 groepen: (1) isometrische 
oefentherapie met de voet in plantairflexie ofwel strekken van de enkel, (2) 
isometrische oefentherapie met de voet in dorsiflexie ofwel naar boven buigen van 
de enkel, (3) isotonische oefentherapie en (4) rust. Het doel van dit onderzoek was of 
de verschillende vormen van spieractivatie een direct pijn reducerend effect hebben 
bij patiënten met langdurige klachten van een midportion achilles tendinopathie. 
In deze studie hebben wij aangetoond dat zowel isometrische alsook isotonische 
oefeningen niet zorgen voor een direct pijn reducerend effect in deze populatie. 
Daarop ontraden wij de uitvoering van isometrische oefeningen met het doel om 
pijnklachten direct te doen verminderen, bijv. voorafgaand aan een training. 
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Een andere veelbelovende nieuwe behandeloptie leek een hoog-volume injectie te 
zijn. Het doel van deze injectietechniek is het wegdrukken van de vaatnieuwvorming 
dat veelal gezien wordt bij patiënten met achilles tendinopathie. Het idee is dat de 
nieuwgevormde zenuwtakken die zich vormen naast de nieuwe bloedvaten een 
belangrijke rol spelen bij het langdurig aanwezig blijven van pijnklachten bij patiënten 
met achilles tendinopathie. In hoofdstuk 7 is onderzocht of het toepassen van een 
hoog-volume injectie naast de standaard behandeling zorgt voor een verbetering van 
de klachten. De gedachte van een hoog-volume injectie is dus dat het vaatnieuwvorming 
en nieuwgevormde zenuwtakken rondom de achillespees wegdrukt. Het exacte 
mechanisme wat er rondom een hoog-volume kan worden waargenomen was echter 
nog niet eerder onderzocht. Dit kan gedaan worden door middels echografie te 
kijken naar zogenaamde Doppler flow, waarbij stromingen (bijv. van bloed) kunnen 
worden gevisualiseerd middels kleuren. Wij hebben een dubbelblinde, placebo-
gecontroleerde gerandomiseerde klinische studie uitgevoerd, waarin 80 patiënten 
met langdurige klachten van midportion achilles tendinopathie geïncludeerd zijn. 
Alle patiënten voerden gedurende 24 weken opbouwende krachtoefeningen van de 
kuitspieren uit (standaard behandeling) en werden geloot om ofwel een hoog-volume 
injectie (50 ml) te ontvangen ofwel een placebo injectie (2 ml). Bij de placebo injectie 
werd verwacht dat dit niet zou zorgen voor het wegdrukken van de bloedvaten en 
daarmee geen toegevoegde waarde zou hebben. De injectievloeistof bestond uit 
een zoutoplossing en een pijnstiller voor beide injecties. In dit onderzoek hebben 
wij aangetoond dat een hoog-volume injectie geen toegevoegde waarde heeft naast 
de standaard behandeling bij patiënten met langdurige klachten van een midportion 
achilles tendinopathie. Op basis van deze resultaten raden wij het gebruik van de 
hoog-volume injectie af als behandeling voor patiënten met midportion achilles 
tendinopathie. 
Vervolgens is de oppervlakte kwantificatie methode gebruikt om het mechanisme van 
de hoog-volume injectie verder te onderzoeken. In hoofdstuk 8 zijn de echografische 
uitkomstmaten gepresenteerd van de gerandomiseerde klinische studie waarin de 
effectiviteit van een hoog-volume injectie bij patiënten met langdurige klachten van 
een midportion achilles tendinopathie is onderzocht. Wij hebben aangetoond dat 
Doppler flow niet afnam rondom de hoog-volume injectie en bij controle afspraken 
na 2-24 weken in vergelijking met de placebo behandeling. Er was sprake van een 
significante afname van de Doppler flow direct na de hoog-volume injectie, echter 
eenzelfde afname werd gezien in de placebo groep. Hierdoor wordt deze afname 
meest waarschijnlijk verklaard door inactiviteit en niet door de hoog-volume injectie 
zelf. Daarnaast was de hoeveelheid Doppler flow één uur na de injectie alweer 
terug op het niveau van voor de injectie. De bevindingen in deze studie maken een 
mechanisch effect van de hoog-volume injectie onwaarschijnlijk. Daarnaast hebben 
wij in deze studie aangetoond (1) dat de Doppler flow bij aanvang van de studie niet 
192
Appendices
de prognose van de patiënt-gerapporteerde uitkomstmaat beïnvloed en (2) dat de 
mate van verandering in Doppler flow het beloop van klachten niet beïnvloed. 
In hoofdstuk 9 worden de resultaten uit het proefschrift beschreven in relatie tot 
elkaar en de huidige wetenschappelijke literatuur. Er worden daarnaast aanbevelingen 
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